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ABBREVIATIONS
α-PVP  alpha-pyrrolidinopentiophenone
AM-2201 synthetic cannabinoid; 1-(5-fl uoropentyl)-3-(1-naphthoyl)indole
CI  chemical ionisation
CNS  central nervous system
mCPP  meta-chlorophenylpiperazine or 1-(3-chlorophenyl)piperazine
3,4-DMMC  3,4-dimethylmethcathinone
DDD  Defi ned daily dose. Th e assumed average maintenance dose per day for a 
  drug used for its main indication in adults
2-DPMP desoxypipradrol or 2-benzhydrylpiperidine or 2-diphenylmethylpiperidine
DRD  drug-related death
DUI  driving under the infl uence (of alcohol or drugs or both)
DUID  driving under the infl uence of drugs
ECD  electron capture detection
EI  electron ionisation
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EWS  early warning system
FIMEA  Finnish Medicines Agency
GABA  gamma–aminobutyric acid
GC  gas chromatography
GHB  gamma–hydroxybutyric acid
HP-GC-FID headspace gas chromatography with fl ame ionisation detection
HRMS  high–resolution mass spectrometry
JWH-018 synthetic cannabinoid; 1-pentyl-3-(1-naphthoyl)indole
LC  liquid chromatography
LLE  liquid-liquid extraction
MDEA  3,4-methylenedioxy-N-ethylamphetamine
MDMA  3,4-methylenedioxy-N-methylamphetamine or ecstasy
MDPV  3,4-methylenedioxypyrovalerone or 
  1-(3,4-methylenedioxyphenyl)-2-pyrrolidino-1-pentanone
MePPP  4’-methyl-α-pyrrolidinopropiophenone
MRM  multiple reaction monitoring
MS  mass spectrometry
MS/MS  tandem mass spectrometry
NPD  nitrogen-phosphorus detection




SPE  solid phase extraction
t.i.d.  three times daily (lat. ter in die)
t½  elimination half-life
TOFMS  time-of-fl ight mass spectrometry
UNODC United Nations Offi  ce on Drugs and Crime
Vd  volume of distribution
ABSTRACT
Driving under the infl uence of drugs (DUID) can adversely aff ect driving skills in numerous ways 
and put lives at risk. Legal approaches to DUID vary considerably from country to country, even 
within Europe, and, in the last decades the emergence of new psychoactive substances (NPS) 
has further complicated the scene. DUID is an unlawful act if the substance taken is banned 
or impairs driving. Th e latter is hard to defi ne and prove, putting pressure on governments 
to ban NPS as quickly as possible in order to protect the public by facilitating enforcement of 
DUID laws. However, banning requires knowledge on several aspects of NPS such as prevalence, 
pharmacology, abuse potential and toxicity. Up-to-date, evidence-based information on NPS 
is needed by legislators, toxicologists, clinicians, and other health care professionals. Such 
information would enable potential drug users and the public to be more aware of the risks 
associated with illicit use of NPS. Th is study aimed to add to the knowledge of the NPS most 
relevant in Finland. 
In this thesis, the prevalence, blood concentrations in drivers and in post-mortem cases, 
and demographic details of 3,4-methylenedioxypyrovalerone (MDPV) and desoxypipradrol 
(2-DPMP), were investigated. Changes in prevalence and other characteristics of MDPV were 
monitored over a time span covering a period before its banning as well as a few years aft er 
banning. Phenazepam, a Russian therapeutic benzodiazepine now illegal in Finland, was studied 
by examining both DUID and post-mortem cases. Th e use by apprehended drivers of pregabalin, 
a prescription anticonvulsant with therapeutic indications for neuropathic pain, partial seizures 
and generalised anxiety disorder, was also studied.
Th e results of this study showed that DUID cases provide a valuable source of information 
on NPS prevalence and user profi les. However, little specifi c information could be gained about 
the impact on driving performance and health risks of NPS mainly due to the fact that NPS were 
usually used together with a spectrum of other psychoactive substances. It could, however, be 
concluded that all of the studied NPS were frequently detected in the samples collected from 
apprehended drivers and, in the case of MDPV, the prevalence changed with time. Th e number 
of MDPV-positive cases among apprehended drivers decreased by 51.1% aft er the drug was 
banned. Th e concentrations of NPS found in DUID cases were within the range anticipated 
to produce signifi cant adverse eff ects on driving performance, or, in some cases, in the range 
found in post-mortem cases where the drug may have contributed to the fatality. Th e presence 
of the medicinal drug, pregabalin, was found to be connected to abuse rather than appropriate 
medical use since it was in most cases found in concentrations higher than those recommended 
for therapeutic use and together with illegal drugs such as amphetamine or cannabis. In post-
mortem cases positive for MDPV, the prevalence of suicide was much greater than in fatalities 
related to other drugs. 
Th ree independent registries, namely the DUID toxicology data, the post-mortem 
toxicology database, and court documents, were examined to gain novel information on the 
characteristics of NPS use and those abusing them. Th e large number of cases studied produced 




Th e last ten or twenty years have brought tremendous change to the illicit drug market. Th e 
rapid emergence of new psychoactive drugs (NPS) is a growing problem all over the world and 
constantly creates challenges to toxicologists and health care professionals dealing with drug 
users. One of the reasons for the popularity of these drugs is the widespread availability and easy 
access to the substances through the Internet. Drug users seem to be willing to try substances 
that have gained attention in the media and in Internet forums despite the lack of scientifi c data 
on the potential harm they may cause. 
According to the United Nations Offi  ce on Drugs and Crime (UNODC), NPS are defi ned 
as “substances of abuse, either in pure form or a preparation, that are not controlled by the 1961 
Single Convention on Narcotic drugs or the 1971 Convention on Psychotropic Substances, 
but which may pose a public health threat” [ 1]. Probably the best known group of NPS are 
synthetic chemicals (“designer drugs”) that have been designed to imitate the structure and/
or eff ects of more established drugs. Th ey may initially have been discovered a long time ago 
while developing new molecules for medicinal use. Th e motivation for manufacturing such 
substances in the present context is to circumvent the legal consequences associated with 
the traditional illegal drugs. In late 1970s, more and more clandestine laboratories started 
synthesizing “designed” substances that resembled controlled or banned substances but were 
not yet regulated. Th is manufacturing included, and still includes, nearly all types of drugs from 
opioids to phencyclidine analogues [2]. Manufacturing these substances is relatively easy, their 
distribution and ordering via the Internet is simple and the legal consequences if caught are 
mild or non-existent. Th e risk of being caught is very low due to the fact that many NPS cannot 
be screened for right aft er their introduction to the drug market since analytical methods and 
reference material are usually not available. Consequently, the constant demand of new drugs 
and the ease of manufacturing them have led to a vicious circle in which authorities struggle to 
ban new substances while manufacturers create new substances at an accelerating pace (Fig. 1). 


















Many of the NPS are stimulants, such as cathinone derivatives resembling the original 
substance obtained from chat (Catha edulis, khat), and several possess hallucinogenic properties. 
Synthetic cannabinoids have also gained much exposure in the communities of illicit drug users 
in recent years, albeit less in Finland. In addition to synthetic chemicals, the term “NPS” also 
includes abused plant derived substances such as mitragynine and Salvia divinorum.
Driving under the infl uence of drugs (DUID) has a major detrimental impact on traffi  c 
safety in Finland and all over the world. In Finland, a drug analysis is requested in about 4000 
traffi  c cases every year. At least one psychoactive substance is detected in over 90% of the cases. 
Since all Finnish DUID samples are analysed in one central laboratory and reported to the 
National Bureau of Investigation, the analysis results form an excellent source to explore the 
prevalence of diff erent drugs. 
Th e zero-tolerance law for illegal drugs in DUID was introduced in 2003 in Finland. 
Among other things this means that the driver does not need to show signs of impairment but a 
suspicion (in most cases that of a police offi  cer) is suffi  cient for bringing the suspect for a blood 
test. Th e tests for impairment or road-side sobriety tests, that in many countries are mandatory 
before proceeding to further examinations, have been shown to be ineffi  cient in detecting 
driving impairment, especially in cases of stimulant use [ 3, 4, 5]. Tolerance can be formed towards 
some elements of the drug eff ects, which can further complicate the interpretation of sobriety 
tests. Some countries, e.g. Norway, have set penalties that are graded according to the levels of 
diff erent drugs found in blood [6]. In Finland, the zero-tolerance law means that a person is not 
allowed to operate a motor driven vehicle aft er consuming substances listed in the Narcotics 
Act in such a manner that, during or aft er driving, the substance at issue or its metabolite is 
detectable in the blood of the driver [ 7]. If the drug in question is approved for medical use 
in Finland and the driver has a valid prescription for the drug, the blood concentration must 
be within the therapeutic range and the person should not show signs of impairment. Before 
having been banned, most NPS fall outside of this law. Drivers with unbanned substances usually 
escape prosecution for DUID because of the diffi  culties in making a legally valid determination 
of driving impairment. Even though the authorities are diligently working on controlling new 
drugs, the manufacturers seem always to be a couple of steps ahead. Th e sooner the necessary 
scientifi c information is available to the authorities on the new substances, the sooner the process 
of banning can be started. 
In addition to DUID cases, knowledge of NPS is especially valuable in toxic emergencies, in 
the treatment of drug addicts and in post-mortem investigations. If no information is available 
to the clinician or forensic pathologist on the substances present in their cases, it is diffi  cult to 
assess the relevance of the substance for the case. 
Data obtained from hospital discharge registries are incomplete because non-fatal poisoning 
cases are seldom confi rmed by laboratory analysis in Finland. In contrast, toxicological 
results from Finnish post-mortem investigations form a comprehensive database covering 
all the analytical results from the nearly 13% of deceased every year that undergo a thorough 
toxicological analysis in connection with the medico-legal examination. Comparing this data 
with the DUID material gives valuable insight into the drug situation in Finland. 
In the present study, the prevalence and signifi cance of certain selected NPS were examined 
in DUID cases in Finland. For comparison, the post-mortem cases positive for these substances 
were assessed. Th ese substances were among those added to the list of drugs screened for in 
routine DUID procedures because Finnish Police and Customs were reporting their detection 
in material confi scated from importers or dealers of illegal drugs and it seemed likely they were 
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entering the local recreational drug marketplace. Of the NPS that were included in the screening, 
the substances selected for inclusion in this thesis were the ones that had been frequently detected 
in the samples from the apprehended drivers. Th e studied substances include two stimulant NPS 
(MDPV and 2-DPMP), and two sedatives, including one older benzodiazepine molecule that is 
not in medical use in the western world (phenazepam) and one medicinal drug that has recently 
been noticed to possess considerable abuse potential (pregabalin). 
By developing the techniques for the monitoring of drug use, traffi  c safety can be improved 
by means of informing drivers of the risks associated with recreational use of drugs and also by 
enabling surveillance and legislation. People working with drug addicts need information about 
geographical distribution of NPS usage. National and international drug prevention and early 
intervention programs greatly benefi t from new information about NPS and medicinal drug 
abuse.
Given the multitude of aspects and problems associated to of the use of new, untested and 
uncontrolled psychoactive substances, scientifi c studies on NPS are crucial for many reasons:
 Health care professionals need evidence-based and up-to-date information when treating 
patients abusing NPS.
 Forensic toxicologist and pathologists need information on prevalence, blood 
concentrations and drug use patterns when developing new methods and interpreting 
analytical results.
 Government authorities need all the available information for regulatory purposes as well 
as for planning intervention strategies.
 Th e public needs to be informed about the risk associated with the use of NPS.
Understanding diff erences in drug use patterns can help in recognising drug users and the 
problems connected to diff erent forms of addiction. 
Introduction
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2 REVIEW OF THE LITERATURE
2.1 Drug use, abuse and addic  on
UNODC has estimated that about 243 million people (5.3% of all 15-64 year olds), took illicit 
drugs at least once in 2012 [1]. Much less information is available about NPS prevalence and 
user profi les [8]. For example, it is not known whether the users of NPS also use the more 
established, banned or controlled, older drugs, or, whether there are users who experiment with 
new substances in order to avoid the legal consequences associated with illegal drugs or to gain 
new experiences. NPS have in any case clearly established their presence in the drug scene. In 
2014, 101 completely new psychoactive substances were reported to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), raising the number of monitored substances 
to more than 350 [ 9].
Even though Finland is a small country at the far edge of the western world, a surprisingly 
large number of newly detected substances are reported to the EMCDDA by the Finnish 
authorities every year. A large amount of information on new emerging drugs can be obtained 
from the reports of drugs confi scated by Customs. In 2013, the Finnish Customs detected about 
100 diff erent NPS of which 20 were detected for the fi rst time [ 10]. Th e most important group 
of NPS in terms of prevalence and problems for users in Finland have been the new designer 
stimulants. Th e history of stimulants being very popular in Finland and other Nordic countries 
has apparently created a culture where NPS are welcomed and appreciated by users of illegal 
drugs [ 11]. 
According to statistics submitted to EMCDDA concerning the year 2012, 2.3% of Finns 
aged 15–64 years had used amphetamines at some time in their lives; a prevalence that was lower 
than the mean for the European Union (3.4%) and also lower than in Sweden (5.0%) and the UK 
(10.6%). However, the 2012 data also showed that prevalence of use in the previous 12 months 
among Finnish youth and young adults aged between 15–34 (1.6%) was higher than in any of 
the aforementioned countries (EU 0.9%, Sweden 1.5%, UK 1.1%) [ 12]. Among those in Finland 
seeking treatment for their drug use, for 80.4% the main route of amphetamine administration 
was by injection, which also is higher than the mean for the EU (48%) or for Sweden (76.5%) and 
the UK (26.1%) [12]. 
Most researchers acknowledge the following three stages in the use of drugs: (1) recreational 
drug use – meaning sporadic use one or several drugs, (2) escalated drug use, and (3) addiction – 
meaning the loss of control in respect of drug use [13]. Recreational drug use means the use of a 
drug (legal or illicit) with the intention of achieving positive feelings. However, most recreational 
drug users do not become drug addicts [14]. For a sub-set of recreational users, what starts as 
voluntary drug use or isolated experiments with drug use, may eventually proceed to compulsive 
drug use (addiction). 
Drug addiction or substance dependence is a serious social problem creating costs and 
suff ering for those using drugs, the people around them and society. As defi ned by the diagnostic 
criteria in the International Classifi cation of Diseases (ICD 10th edition), dependence syndrome 
includes at least three of the following:
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1. A strong desire or sense of compulsion to take the substance,
2. Diffi  culties in controlling substance-taking behaviour in terms of its onset, termination, 
or levels of use,
3. A physiological withdrawal state when substance use has ceased or been reduced,
4. Evidence of tolerance,
5. Progressive neglect of alternative pleasures or interests because of psychoactive substance 
use, increased amount of time necessary to obtain or take the substance or to recover 
from its eff ects, 
6. Persisting with substance use despite clear evidence of overtly harmful consequences 
[ 15].
In the similar classifi cation by the American Psychiatric Association used in the US, the former 
disorders “substance abuse” and “substance dependence” have been combined into a new concept 
“Substance use disorder” (SUD) [16].
It has been suggested that the so-called “normalisation” of the use of certain psychoactive 
substances that has occurred in recent years has reduced the barriers to experimenting with 
drug use [17]. However, the major factors driving drug use can be roughly categorised into: 
(1) the urge to feel good and (2) the need to feel better. Th e fi rst, “positive re-enforcement”, 
results in a pleasurable “high” which users wish to experience repeatedly. Th e second, “negative 
re-enforcement”, can be seen as “self-medication” of negative feelings or other conditions 
[18,19,20]. Sometimes self-medication is needed to control the side-eff ects of other recreational 
drugs. 
According to one of the largest surveys of recreational drug use ever conducted, in which 
over 40 000 Americans were asked questions about alcohol and drug use and related disorders, 
2% of the study population met the criteria for drug use disorder [21]. In an earlier Finnish 
study, “problem drug users” were defi ned as individuals that have taken amphetamine or opioids 
in a manner that caused adverse social or health eff ects that in turn prompted intervention 
by the authorities resulting in the individual’s name having been entered in a national offi  cial 
register (e.g. hospital discharge register, the national police information system, the register of 
drivers caught driving under the infl uence of drugs, hepatitis C cases in the national infectious 
diseases register) [ 22]. Th e number of such problem drug users in Finland in 2012 was estimated 
to be between 18 000 and 30 000 individuals corresponding 0.55–0.90% of the population aged 
between 15 and 64 [22]. 
Substance dependence also impacts driving in several ways, one of which is that an individual 
who fulfi ls certain drug-use criteria is not permitted to possess a driving licence. According to 
the EC Directive on driving licences, an applicant who is dependent on psychotropic substances 
or regularly uses them shall not be issued a driving licence [23]. It remains for the member 
states to decide how the fi tness to drive is tested or which criteria are used in assessing possible 
substance dependence.
In Finland, the prerequisites for being fi t to drive are regulated in various laws. Th e request 
for a physician to evaluate the fi tness to drive of a suspected drug-dependent individual is made 
by the Police who also make the fi nal decision of whether or not the person is granted a driving 
licence [24]. However, a signifi cant proportion of DUI off enders do not possess a valid driving 
licence and are thus outside of this evaluation process.
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2.2 New psychoac  ve substances
Th e number of NPS reported yearly to the EMCDDA has grown every year since 2008 [9]. In 
many countries, NPS are sold in so called “head shops” and the drugs are sometimes labelled “not 
for human consumption” [ 25, 26]. Th ey may be marketed as “bath salts”, “plant food” or “herbal 
incense” in order to circumvent the law. In Finland, however, the main source of NPS has always 
been the Internet and the drugs are mainly purchased as “research chemicals” or transported for 
personal use from abroad [12,27]. At present, there is very little scientifi c data available on the 
prevalence of NPS in Finland.
In the last few years, NPS markets in the “darknet” or “deep net” has become an issue. 
“Darknet” is a series of anonymised websites that users with special knowledge can access in 
order to buy illegal products such as drugs, guns, pornography etc. Transactions are encrypted 
and payments made with Bitcoins, thus assuring anonymity of both parties [28,29].
All new stimulant drugs, as is the case with the more established illegal stimulants 
amphetamine, cocaine and ecstasy (MDMA), act by increasing the levels of extracellular 
neurotransmitters dopamine, serotonin and noradrenaline in the central nervous system (CNS) 
[30]. Th e increased levels of these neurotransmitters mediate the behavioural eff ects of stimulants 
such as hyperactivity, euphoria, and analgesia. In low doses, many of the synthetic cathinones 
have entactogenic eff ects [ 31]. Especially in the US, NPS have become popular in mixtures called 
“psychoactive bath salts” which may contain just one substance or a mixture of a number of 
psychoactive drugs. Th e ingredients of “bath salts” and other “legal highs” that are marketed 
under a certain brand name may change over time [ 32]. 
In addition to the eff ects that the users seek, the structures of many of the NPS predict severe 
adverse eff ects especially when taken repeatedly and in high doses. Most reports on the adverse 
eff ects of NPS involve abuse of synthetic cathinones. Th e most common clinical symptom 
in severe intoxication cases resulting in hospitalisation has been acute psychosis but also the 
following have been frequently reported: paranoia, visual and auditory hallucinations, self-
injurious behaviour, homicidal thoughts, and amnesia [ 33,34]. Some less prevalent eff ects have 
included hyponatremia, cerebral oedema and hypoglycaemia [35,36]. By enhancing sympathetic 
nervous system activity, synthetic cathinones can cause cardiovascular eff ects such as tachycardia, 
hypertension and thrombosis [37,38]. Th e increased serotonergic activity can cause serotonin 
syndrome with the following symptoms: severe agitated delirium, life-threatening hyperthermia, 
rhabdomyolysis, and renal failure [39, 40,41]. 
Since new substances enter the recreational drug marketplace at such a fast pace, research 
on them usually comes later. So far, research on NPS has mostly been limited to case reports, 
measurement of drug levels in community wastewater, custom’s reports on confi scated drugs, 
poison centre data and analysis of pooled urine from portable urinals [42,43,44].
One of the many problems associated with the use of NPS is that the users oft en do not know 
which drug(s) they are taking [45,46,47]. Either the drug has been sold to them as something else 
or they may have purchased a drug with a “brand name” such as “Ivory Wave” or “Super Coke” 
which are mixtures whose content varies with time due to changes in legislation and other factors 
[32]. As potency can vary signifi cantly between diff erent psychoactive substances, selection of 
the appropriate dosage of substances of unknown composition is guesswork and may bring about 
stronger or unwanted eff ects, or toxicity, making this a very dangerous phenomenon. Th us, from 
the users’ perspective, a major risk in taking NPS is dose selection [48]. Since users cannot be 
sure of the identity or dose of the substances they use, the value of survey-type research on NPS 
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that does not involve analysis of biological specimen to identify the drugs and doses involved is 
limited.
Th e motivation for taking NPS, as opposed to older psychotropic substances, probably varies 
between individuals but may include e.g. the need to circumvent the legal system by ordering 
or using uncontrolled substances, or curiosity. Th e desired eff ects may include e.g. feeling of 
increased energy and vigilance, increased libido, empathy, euphoria, alertness and well-being 
and psychedelic eff ects [25,49,50, 51]. 
2.2.1 Non-medical prescrip  on drug use
NPS have also been defi ned more broadly as any substance that has come to the illegal drug 
marketplace within the last 10 to 20 years or where there is evidence of signifi cant increase in 
abuse of a substance in recent years [52]. Hence the term also includes many abused prescription 
drugs that were not designed for recreational use but rather were developed and approved by 
regulatory authorities to treat specifi c health issues. With time, those medicinal products with 
appropriate pharmacological properties may gain a reputation among users of illegal drugs and 
eventually become abused. Th is is unfortunate since restricting the availability of medicinal 
drugs due to problems with abuse and dependency always complicates the lives of those patients 
who benefi t from the therapeutic eff ects of the drug.
Several diff erent terms are used to describe medical uses of prescription drugs which were 
not specifi cally endorsed by regulators when the drug was approved to treat disease. “Off -label 
use” means the therapeutic use of the drug, as prescribed by a physician, for an indication, age 
group, dosage etc. that is not listed in the approved documentation (label) for the drug. Off -label 
use is legal and medically acceptable if pursued on the initiative and under the supervision of a 
physician in the best interest of the patient. “Misuse” of prescribed drugs is use in an eff ort to 
treat the condition for which the drug was described but in ways that were not intended by the 
prescribing physician. Ways of misusing medicinal products are only limited by the imagination 
of the user; it can include use of higher doses, more frequent dosing, using the drug for longer 
periods than intended, changing the routes of administration, or inappropriate concomitant 
use of other drugs [53]. Misuse can have many causes, including ignorance or error on the 
part of the patient, or an eff ort to achieve a greater therapeutic eff ect. “Drug abuse” or abuse 
of medicinal drugs refers to non-prescribed use of one or several drugs in order to achieve 
certain pharmacological eff ects; frequently eff ects on the CNS such as improved mental state 
or psychomotor performance. Th e desired eff ects most oft en include tranquillity, euphoria or 
increased alertness. Less common motives for “self-medication” may be achieving weight loss, 
treating insomnia or some undiagnosed medical condition. An additional reason for abusing 
prescription drugs may be to counteract the negative side-eff ects or come-down eff ects of other 
drugs of abuse [54].
Epidemiology of non-medical prescription drug use is oft en studied by conducting 
population surveys. In Finland, the last national survey on drug use concerning the year 2010 
revealed that 6% of all Finns aged between 15 and 69 had ever used sedative, hypnotic or analgesic 
drugs for non-medical purposes [55]. Among the individuals seeking treatment for problems 
related to drug abuse, the percentage of those with sedative medicinal drugs as a primary drug of 
abuse has increased in recent years and was 60% in 2013 [10].
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2.2.2 Chemistry of NPS
New drugs can be grouped in several diff erent ways such as according to the older abused drug 
they resemble, for example designer amphetamines, designer opioids or synthetic cannabinoids. 
Th e structure-based categorization of NPS used by EMCDDA suggests the following groups:
 synthetic cathinones: synthetic derivatives of cathinone which is one of the stimulant 
ingredients of the shrub khat (Catha edulis) [ 56],
 synthetic cannabinoids: chemicals that are designed to mimic the eff ects of 
tetrahydrocannabinol, the main active ingredient of cannabis [57],
 piperazines: a group of chemicals with a piperazine functional group producing mostly 
stimulant/euphoric eff ects [58],
 tryptamines: hallucinogenic compounds structurally related to LSD [59],
 phenethylamines: a large group of substances that may produce stimulant, psychedelic 
and entactogen eff ects [60].
Th e vast majority of the NPS fall into the fi rst three categories [61]. Some of the NPS do not 
fall in any of these classes and are thus categorised as “other” including e.g. plant material and 
medicinal products.
2.3 Analy  cal aspects of NPS
Conventional laboratory and roadside drug testing has been designed to detect the 
traditional abused drugs, namely, amphetamines, cannabis, cocaine, and heroin. Additionally, 
buprenorphine and benzodiazepines may be included. Many of the test batteries in clinical and 
hospital laboratories consist of immunological analyses which are an effi  cient way of rapidly 
screening a large number of samples, without complicated sample pre-treatment procedures and 
at moderate cost per sample. Th e immunological tests are especially useful in situations where 
the initial assumption is that the majority of the samples will be negative. An example of such a 
situation is workplace drug testing. 
Despite the advantages of immunological methods for screening large numbers of samples, 
they have a number of limitations. In cases with potential legal consequences, all positive results 
from immunological testing must be confi rmed by another method. Even though the modern 
immunoassays have been shown to cross-react with some of the NPS [62], current methods 
do not detect the range of analytes relevant in today’s toxicology. Immunoassays are in most 
cases not able to detect the ever expanding variety of NPS that include substances from multiple 
pharmacological categories [63]. Additionally, many abused prescription drugs are not detected 
by current immunological methods. Furthermore, the detection limits of immunological tests 
are oft en much higher than those in chromatography-based screening methods and thus some 
individuals with low drug concentration may escape detection if screened immunologically. 
In many forensic indications, the analytical approach most suited to the screening of a large 
and varying spectrum of abused drugs is liquid chromatography (LC) combined with high-
resolution mass spectrometry (HRMS) [64,65,66,67]. Time-of-fl ight MS (TOF-MS) methods 
have been found to be particularly useful since they incorporate the accurate mass of precursor 
and qualifi er ions, isotopic pattern, and retention time to provide a positive identifi cation. 
LC-TOFMS also enables the preliminary identifi cation of substances for which a reference 
standard is not available [ 68].
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2.4 Substances selected for inves  ga  on in this thesis
Th e NPS studied in this thesis were MDPV, phenazepam, 2-DPMP and pregabalin. Details of 
typical doses, blood concentrations and pharmacology of these substances are given in Table 1.




Th er. range in 
plasma (mg/L) DDD (g)
a T1/2 (h)b Vd (L/kg)c References
MDPV 5–20 - - 1.88 - 20,69
Phenazepam 0.5–2.0 0.030–0.070 - 60 4.7–6.0 70,71 ,72, 73
2-DPMP 1–10 - - 16–20 - 72
Pregabalin 150–800 2.0–8.0 0.3 5–11 0.5–0.6 72,74
adefi ned daily dose (the assumed average maintenance dose per day for a drug used for its main 
indication in adults), belimination half-life, cvolume of distribution
All previous information published in peer-reviewed journals about blood concentrations 
aft er recreational use of the four substances is collected into Table 2. For some drug screening 
indications, such as testing individuals in drug rehabilitation programs, the primary specimen 
for the analysis is urine. Th ese cases were not included in Table 2. Th e material used for analysis 
in the post-mortem studies varied in the reviewed articles and in some cases samples of multiple 
tissues had been analysed. In some studies, the origin of the post-mortem blood sample was not 
mentioned. In cases where results were available from several tissues, the results from femoral 
blood are listed in Table 2.
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Table 2. Published blood concentrations of abused drugs in samples from living individuals and from 
post-mortem (PM) investigations. DUID cases are marked with an asterisk (*).
Substance Concentration (mg/L) Specimen N Reference
MDPV living
0.024 – 0.241 (mean 0.058) Serum 13  75 (Spiller et al. 2011)
* 0.006 – 0.368 (mean 0.100) Blood 8  76 (Marinetti et al. 2013)
0.186 Serum 1 77 (Th ornton et al. 2012)
* 0.0213 and 0.146 Serum 2  78 (Maas et al. 2015) 
0.072 – 0.089 Blood 3 79 (Froberg et al. 2014)
0.124 and 0.306 Blood 2  80 (Adamovicz et al. 2013)
* <0.01 – 0.30 (median 0.05) Blood 33  81 (Griffi  ths et a. 2015)
MDPV PM
0.039 and 0.760 PM blood 2 82 (Wright et al. 2013)
0.17 PM blood 1 75 (Spiller et al. 2011)
0.082 PM blood 1 26 (Murray et al. 2013)
0.44 PM blood 1  83 (Wyman et al. 2013)
0.010 – 0.640 (mean 0.109) PM blood 16 76 (Marinetti et al. 2013)
0.06 – 1.55 PM blood 8  84 (Elliott et al. 2014)
1.0 PM blood 1  85 (Kesha et al. 2013)
0.0222 PM blood 1 86 (Tóth et al. 2013)
0.017 and 0.038 PM blood 2 80 (Adamovicz et al. 2013)
1.2 PM Blood 1 87 (Namera et al. 2013)
Phenazepam living
* 0.076 Blood 1  88 (Kerrigan et al. 2013)
* 0.04 – 3.2 (median 0.17) Blood 11  89 (Stephenson et al. 2013)
1.2 μg/g Blood 1  90 (Mrozkowska et al. 2009)
* 0.120 – 0.870 Blood 3 91 (Burch et al. 2013)
0.49 Serum 1  92 (Dargan et al. 2013)
Phenazepam PM
0.386 PM blood 1  93 (Bailey et al. 2010)
2.52 PM blood 1 94 (Corkery et al. 2015)
0.009 – 0.370 (median 0.076) PM blood 23 95 (Crichton et al. 2015)
2-DPMP living
* 0.356 Serum 1 78 (Maas et al. 2015)
2-DPMP PM
0.025 – 1.16 PM Blood 3 96 (Corkery et al. 2012)
Pregabalin living
29 Blood 1  97 (Grosshans et al. 2010)
Pregabalin PM
0.28 – 110 PM Blood 316  98 (Häkkinen et al. 2014)
0.04 – 23.8 (median 5.18) PM Blood 43  99 (Lottner-Nau et al. 2013)
0.4 – 17.0 (median 5.6) PM Blood 15 100 (Priez-Barallon et al. 2014)
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2.4.1 MDPV
In Finland, one of the most prevalent NPS has been MDPV. It belongs to the chemical class 
of α-pyrrolidinovalerophenones and is a methylenedioxy-substituted analogue of the older 
medicinal stimulant drug pyrovalerone [ 101]. MDPV was fi rst developed by the researchers of 
the pharmaceutical company Boehringer Ingelheim in 1969 [102]. MDPV and other cathinone 
derivatives are structurally closely related to amphetamines – especially MDMA - diff ering mainly 
by a β-keto amine group. Cathinone derivatives such as MDPV, mephedrone and methylone are 
oft en called β-ketoamphetamines (Fig. 2) [103]. Based on their structure, synthetic cathinones 
can be predicted to have similarities in their pharmacological profi le to MDMA analogues [33].
Figure 2. Chemical structures of amphetamine and some cathinones. 
MDPV became available for the users of illegal drugs in Finland around 2007, aft er having been 
identifi ed in recreational drug users elsewhere in Europe some years before [101]. In Finland, 
MDPV was scheduled as a narcotic in 2010 – a process that prompted the amendment of the 
Narcotics Act that now allows for national scheduling without previous listing by other authorities, 
e.g. the United Nations. MDPV is currently banned in all member states of the EMCDDA as well 
as classifi ed as a Schedule I substance by the US Drug Enforcement Administration. Currently, 
MDPV is under consideration by the Commission on Narcotic Drugs (UN) for being placed in 
Schedule I of the Single Convention on Narcotic Drugs [104].
In animal and in-vitro studies, MDPV has been shown to be a potent blocker of dopamine 
re-uptake [ 105,106,107] suggesting a high risk for abuse for the drug by contributing to the 
drug-high and euphoria that are the eff ects that users desire [15]. It is also a potent blocker of 
norepinephrine uptake, which predicts severe cardiovascular eff ects [105]. In severe intoxication 
cases, the following symptoms have been reported: severe agitation, psychosis, violent behaviour, 
hyperthermia, tachycardia, severe serotonin syndrome, organ failure such as rhabdomyolysis, 
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hepatic and renal failure, delusions, hallucinations and paranoia [ 40,75,108,109]. Deaths have 
also been reported [26,40,Table 2].
Th e metabolism of MDPV has been shown to involve multiple diff erent CYP isoenzymes 
and thus the existence of complications from genetic polymorphism or signifi cant drug-drug 
interactions is unlikely [110]. 
In recent studies on community wastewaters from cities around Finland it was shown that 
MDPV was quite prevalent in eastern parts of Finland close to the Russian border [ 111, 112]. In 
one of the studies that measured drugs from wastewaters in 9 diff erent water treatment plants in 
2012, MDPV was exclusively found in the South-eastern city of Savonlinna [111]. In the other 
similar 2012 study, water from 10 treatment plants was examined and MDPV was detected in 
another south-eastern city, Lappeenranta, and also in Helsinki albeit in lower amounts [112].
2.4.2 Phenazepam
Phenazepam (Fenazepam, “Bonsai”) is a long-acting benzodiazepine that was originally 
developed in the former Soviet Union in the 1970s [113]. It has never been in medicinal use in 
Finland nor in other western countries, but is still widely prescribed in Russia and some former 
Soviet countries. Phenazepam was banned in Finland in July 2014.
Phenazepam belongs to the group of 1,4-benzodiazepines. It is structurally similar to other 
benzodiazepine derivatives, for example, diazepam, lorazepam and nitrazepam (Fig. 3).
Figure 3. Th e chemical structure of phenazepam (7-Bromo-5-(2-chlorophenyl)-
1,3-dihydro-2H-1,4-benzodiazepin-2-one).
Since around 2009, a growing number of reports of phenazepam abuse have been published in 
several countries, e.g. USA, UK, New Zeeland, Sweden and Finland [114, 115,Table 2]. Fatalities 
have also been reported [11,116, 117, Table 2]. Phenazepam has been found as a component in 
mixtures of two or more psychoactive substances, such as with synthetic cannabinoids [115]. 
According to several anecdotal user reports in Internet forums, phenazepam is not widely 
used for self-medicating anxiety (unlike e.g. alprazolam) but is rather used for getting “high”. Th e 
users have estimated the potency of phenazepam to be approximately fi ve times that of diazepam.
Similar to other benzodiazepines, phenazepam can slow reaction time and cause drowsiness 
and confusion in drivers [89]. Its long half-life means that adverse eff ects persist and may 






accumulate when re-dosed [88]. Phenazepam has also been suggested to induce amnesia, at least 
at higher doses [Internet forums, 89].
2.4.3 Desoxypipradrol
Desoxypipradrol (2-DPMP, “Daisy”) is an example of the new designer stimulants that are 
actually not so new at all. Th e substance was originally in development for the treatment of 
narcolepsy and Attention Defi cit Hyperactivity Disorder (ADHD) in Switzerland as early as in 
the 1950s [118] but was later withdrawn from development. Th e second appearance of the drug 
started in 2007 when the users began to discuss a new, extremely long-acting substance in their 
Internet forums. In Finland, the fi rst reports of the drug date back to 2008 and it was fi nally 
banned in 2012.
As the name indicates, desoxypipradrol is a desoxy analogue of pipradrol (Fig. 4) which is 
an old CNS stimulant that is not considered to be particularly potent in terms of its stimulant 
properties. Pipradrol resembles amphetamine in its mechanism of action but diff ers from 
it by not causing insomnia, inappetence or post-use depression [119]. It is still used in some 
countries (e.g. South-Africa) under the trade name Alertonic or Meratran to treat conditions like 
narcolepsy, ADHD and symptoms of dementia.
Figure 4. Th e chemical structures of desoxypipradrol [(RS)-2-benzhydrylpiperidine], pipradrol (α,α-
diphenyl-2-piperidinemethanol) and methylphenidate [methyl 2-phenyl-2-(piperidin-2-yl)acetate].
Desoxypipradrol is structurally similar to methylphenidate (Fig. 4) but it is much more potent 
and long-acting [120]. Contrary to methylphenidate, desoxypipradrol cannot be eliminated by 
ester hydrolysis but undergoes complex metabolism [121]. Desoxypipradrol acts by increasing 
the release of dopamine and slowing its re-uptake and its eff ects are suggested to be greater than 
those of cocaine [122].
Th e popularity of desoxypipradrol as a recreational drug seems to be very regional. Th ere 
are only few case reports of desoxypipradrol use from other countries [123,124, Table 2] whereas 
in Finland it gained massive publicity in 2010 when several young people developed severe side-
eff ects from using the initially unknown substance called “Daisy”. 
According to some discussions on Internet user forums, the long half-life of desoxypipradrol 
makes it popular with individuals trying to remain alert through the night, such as students or 
over-night drivers.













Pregabalin is a relatively new medicinal drug that is widely used around the world for the 
treatment of epilepsy, neuropathic pain and fi bromyalgia. It has been available for medicinal use 
since 2004. For quite some time it was thought to lack any potential for abuse, which lead to 
suggestions that it would be useful for the treatment of anxiety and other indications in drug 
addicts and in alcohol detox [125,126]. Pregabalin has been approved for the treatment of 
generalised anxiety syndrome in Europe since 2006 but is still not approved for that indication 
in the US. In the last few years, reports of misuse and abuse have appeared [ 98,127, 128, 129, 
130,131,132, Table 2] and today pregabalin is a prime example of prescription drug abuse. 
Pregabalin (Fig. 5) is a structural analogue of gamma-aminobutyric acid (GABA) and, 
although inactive at all GABA receptors, it possess GABA-mimetic properties [129, 133]. It 
reduces the release of neurotransmitters, such as noradrenaline, glutamate and acetylcholine 
from synapses thus producing its therapeutic eff ects: prevention of seizures in the treatment 
of epilepsy, analgesia and anxiolytic activity. Th e latter are similar to those induced by 
benzodiazepines or alcohol and can potentially be of interest for the users of recreational drugs 
[133 , 134]. Additionally, pregabalin has been shown to induce euphoria is some individuals 
[ 135,134] and to potentiate the eff ects of opioids [98].
Figure 5. Th e chemical structures of GABA (4-aminobutyric acid) and pregabalin
[(S)-3-(aminomethyl)-5-methylhexanoic acid].
Th e eff ects of pregabalin on driving have been studied in driving simulator studies with healthy 
volunteers but no major eff ects were observed [ 136, 137]. In studies of Finnish drugs users, the 
frequency of pregabalin detection in post-mortem investigations has been steadily increasing 
[11, Table 2].
2.5 Driving under the infl uence of drugs
It has been estimated that of the general population of car drivers in Europe at any given time, 
1.90% drive under the infl uence of illicit drugs [138]. Th ere are, however, major diff erences in 
the numbers between individual countries, even among neighbouring countries, due to cultural 
diff erences and diff erences in law enforcement and prescription policy [139,11]. 
In Finland, the majority of DUI cases arise from a traffi  c violation, e.g. accidents or failure 
to follow the traffi  c rules [ 140]. Every year in Finland, over 20 000 drivers are apprehended for 










driving under the infl uence of drugs or alcohol. In the majority of the cases, the substance used is 
ethyl alcohol. In about 4000 DUI cases yearly the suspicion is of drugs.
2.5.1 Screening and laboratory analy  cs in DUI cases
As per the instructions of the Ministry of the Interior the primary method for confi rming 
suspected driving under the infl uence of alcohol is the evidential breath analyser. In cases of 
suspected drug use, the driver is usually fi rst subjected to a road-side oral fl uid drug screening 
test (e.g. DrugWipe®) and later a blood test is taken in the nearest health centre by a physician or 
phlebotomist. Even though urine is the preferred analysis material in many clinical and forensic 
settings, in DUID cases, the primary material for analysis in most countries is blood or serum. 
For screening purposes, oral fl uid is increasingly being used due to the non-invasive nature of 
sample collection [ 141]. Blood and oral fl uid samples can be collected shortly aft er a driving 
incident occurred and drug levels measured in such samples have a direct bearing on impairment 
at the time of the incident. In contrast, drug levels measured in urine refl ect blood levels over an 
extended window of time that includes a period prior to the driving incident and may therefore 
be irrelevant in assessing impairment [142]. Moreover, a blood sample is required by the law for 
DUID investigations in several countries, including Finland [7]. 
Th e process for roadside and laboratory tests in association with suspected DUI cases is 
illustrated in Figure 6.
Figure 6. Process chart of the initiation of a DUI investigation.
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In Finland, the extent of the drug screening that is performed on a particular blood sample 
depends on the severity of the preliminary charges which are determined by the police offi  cer 
in charge of the preliminary investigation. A prosecutor only comes to the picture aft er the 
preliminary investigation is fi nished. In DUI cases, the preliminary prosecution – and later the 
actual charges – can either be ”driving while intoxicated” or “driving while seriously intoxicated” 
depending on the circumstances, clinical assessment of impairment and the arresting police 
offi  cer’s evaluation of the situation. In alcohol cases the division into the two categories is simple: 
if the roadside breath test shows an alcohol concentration between 0.50 and 1.19 g/kg the off ence 
is ordinary DUI. If the alcohol concentration is equal or above 1.20 g/kg the off ence is graded as 
aggravated (“driving while seriously intoxicated”). Th e charges may change later if the results of 
the analysis of the blood sample diff er from the screening results. 
In drug cases, the categorisation is more based on the observations of the arresting 
police offi  cer and other data on the incident. Th e fi nal charges (normal vs. aggravated) will be 
determined at the end of the preliminary investigation.
2.5.2 Impairment tes  ng
One of the means available to study driving impairment caused by drugs is to examine 
competence tests performed when drivers are apprehended for DUID. Th e standardised clinical 
examination in Finland consists of 15 tests of motor, vestibular, and mental impairment, such as 
walking on a straight line, fi nger-fi nger test, speech, pupil size and reaction to light, and mood. 
In other countries, several diff erent kinds of impairment and sobriety tests are used. All of these 
tests share the same limitation in that sedative induced impairment is relatively easy to detect 
whereas the eff ects of stimulant use oft en remain undetected. Even sedative use can sometimes 
be missed: In Norway, many of the drivers examined passed the tests even with considerable 
blood concentrations of zopiclone or alcohol [143].
Th e test used in Victoria, Australia has shown reasonable success in detecting impairment 
following recent use of cannabis [144] but is less successful with amphetamines [3]. Th e road-
side impairment test used in Norway shows a positive concentration-impairment relationship for 
amphetamines [ 145]. Th e German procedure is most eff ective in detecting impairment in opiate 
users but its performance with other classes of drugs was found to be adequate for screening 
purposes [146]. 
2.5.3 Recidivism and a   tudes towards DUID
According to earlier studies from Sweden and Finland, recidivism is very common among 
drivers arrested for DUI [ 147, 148]. Th is is especially prominent in drivers using drugs when 
compared to those driving under the infl uence of alcohol only [148]. Depending on the study, a 
third [148] or even nearly half [147] of the drivers re-off ended aft er the fi rst arrest. In the Finnish 
study, the use of stimulants in particular was found to be associated with an increased incidence 
of early re-arrest [148]. 
Th e attitude of the driver towards DUI has been suggested to diff er for those driving under 
the infl uence of drugs versus those driving under the infl uence of alcohol. Drivers under the 
infl uence of alcohol oft en regret their behaviour aft erwards while people driving under the 
infl uence of drugs already consider themselves to be outside the law as a result of using illegal 
drugs and show less regret for the DUI off ence [ 149]. As compared to drug use itself, the illegality 
of the driving behaviour is in their opinion considered a minor off ence [ 150]. Moreover, those 
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driving under the infl uence of either drugs or alcohol consider the risk of being caught to be low 
[150].
Th ose committing DUID may also assume that the drug use will not increase their risk of 
an accident but perhaps even improve their driving skills [149,150]. Drivers have been shown to 
be unable to recognise their driving impairment caused by drugs [ 151]. Some may get part of the 
thrill of drug use from driving while high [150]. Avoiding driving under the infl uence of drugs 
would require signifi cant eff ort by users and likely cause considerable inconvenience (such as 
delays in achieving their next “high”). In addition, the fact that they are illicit drug users means 
that they are already failing to regulate their behaviour. Th ese factors combine to make DUID 
very diffi  cult to prevent [149].
2.5.4 Eff ects of drugs on driving performance
All drugs that aff ect the CNS – whether prescribed or illegal drugs – may cause driving 
impairment by aff ecting crucial driving skills such as reaction time, judgment and processing 
simultaneous tasks [152]. Many of the eff ects are dose-dependent even in experienced users 
[ 153] although for some of the eff ects tolerance may develop with time.
Sedatives, such as cannabinoids, opioids, benzodiazepines and gamma-hydroxybutyric acid 
(GHB) can aff ect ability to concentrate and can cause drowsiness, lack of coordination, altered 
perceptions, memory impairment, and slower reaction time, all of which all are detrimental 
for driving [154,155,156, 157]. Sometimes the eff ects of the drug (e.g. cannabis) cannot be 
identifi ed by the driver so that they may consider themselves competent while actually being 
impaired [158]. Older individuals are in general more sensitive to the eff ects of sedatives, such as 
benzodiazepines, and the eff ects also last longer [159]. 
Stimulants, such as amphetamines, cocaine, and synthetic cathinones, can increase the 
driver’s tendency to take unnecessary risks while at the same time aff ect concentration and impair 
vision [145,160,161,162]. At least in low doses, however, stimulants may improve psychomotor 
performance for example by enhancing alertness [163]. Combining drugs that have similar 
eff ects on the CNS may cause synergistic eff ects so that the overall eff ect is greater than the sum 
of the individual eff ects [157]. Under the infl uence of amphetamine-like stimulants, users oft en 
do not show any signs of impairment in the test systems available for routine screening, although 
impairment with such drugs is detected in more sophisticated laboratory systems; this can make 
prosecution in such cases challenging [164].
Opportunities to study the pharmacology and toxicology of NPS are limited for obvious 
ethical reasons. Th e vast majority of the publications about NPS describe analytical determination 
of the substances or case reports. Th ere is very little data available so far about prevalence of NPS 
among drivers or how the NPS actually aff ect driving performance. However, when taking NPS, 
the user is likely seeking eff ects similar to those of the more traditional abused drugs. Th us the 
pharmacology of NPS is likely to have some similarity to traditional abused drugs and adverse 
eff ects on psychomotor performance are likely to be similar. Although this is a reasonable 
assumption, it is only an assumption and important diff erences may exist that could be revealed 
in driving simulation studies with volunteer subjects; such studies (administering unapproved 
drugs with no safety data to healthy volunteers), however, would be unethical and are unlikely to 
be performed. Th e typical neurological and psychological eff ects of synthetic cathinones, such as 
agitation, dizziness, panic, paranoia and hallucinations, can have major detrimental impact on 
driving performance [78]. 
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Some reports describing the driving impairment caused by NPS have been published in 
recent years although they are reports of individual cases of DUID rather than planned trials. 
In Seattle, USA, a driver apprehended for poor driving showed the following symptoms aft er 
being apprehended: slurred speech, bloodshot watery eyes, dilated pupils, involuntary muscle 
movements and an elevated pulse and blood pressure. In toxicological analysis of the driver’s 
blood, α-PVP (0.063 m/L), methylone (0.0061 mg/L) and ethylone (positive) were found [165]. 
On the basis of the clinical examination, he was judged by the examining physician to have been 
under the infl uence of CNS stimulants and was placed under arrest. Th is is a rare case of the 
use of synthetic cathinones with no other psychoactive substances present and it thus provides 
important information about the possible eff ects of a particular class of NPS on psychomotor 
performance. 
Another study from the US (Ohio) reports on seven drivers positive for MDPV over a period 
of about 2 years. Some of the subjects had other psychoactive substances present as well, but 
rarely in pharmacologically relevant concentrations [76]. An interesting fi nding in this particular 
study was that blood cathinone concentrations did not appear to correlate with the observed 
driving impairment. Some relatively low concentrations were associated with major behavioural 
changes. Th e authors of that study suggested that this might be related to the dysphoria (“crash”) 
commonly experienced aft er a prolonged stimulant high [76,166].
In a German study, the toxicology results from six DUID cases were presented together 
with information about signs of impairment. Many of the drivers showed concomitant use of 
other drugs together with the studied phenethylamines but at least in some cases the observed 
impairment was suggested to result from the use of MDPV and desoxypipradrol [78]. 
Th ere are more data available on driving under the infl uence of synthetic cannabinoids. A 
study from Germany described eight individuals examined toxicologically for DUI of synthetic 
cannabinoids. Only one of the subjects had another psychoactive substance, namely alcohol, in 
their blood and all showed clear signs of impairment [167]. 
In Norway, 2.2% of 726 drivers apprehended for DUI and analysed for synthetic 
cannabinoids were found to be positive for at least one of them. However, the concomitant use of 
other drugs made it impossible for the researchers to evaluate the role of synthetic cannabinoids 
in the observed driving impairment of the subjects [168]. In Pennsylvania, USA, synthetic 
cannabinoids were found to have caused cognitive and psychomotor impairment to 12 drivers 
apprehended for unsecure driving [169].
Phenazepam has also been detected in DUID cases in the past few years but there is no direct 
assessment of its impact on driving. However, being a benzodiazepine, the eff ects of phenazepam 
on driving skills are likely to resemble the eff ects of diazepam although its long elimination half-
life and greater potency suggest that the induced impairment is also likely to be stronger and/or 
last longer [153]. In addition, due to the long elimination half-life of phenazepam (approximately 
60 hours), the risk of unintentional intoxication by rapid re-dosing may be an issue [90].
Th e only information on driving under the infl uence of pregabalin comes from two driving 
simulator studies with healthy volunteers [136,137]. In one of the studies, the administered 
dose resembled the typical therapeutic dose of 150-600 mg [ 170] and it caused minor, transient 
impairment on certain psychomotor skills [136]. In the other study, the administered dose was 
low (75 mg on two consecutive days) and it mainly caused sleepiness in the tested volunteers 
[137]. Th e reported side eff ects of pregabalin, such as dizziness, sleepiness and decreased 
concentration [170] suggest that the drug may cause impairment, especially taken in high 
 concentrations [171].
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2.6 NPS in post-mortem cases
In Finland, about 12000 forensic autopsies are performed every year. In about 6000 of these cases 
post-mortem toxicology is requested; as a result, toxicology is performed on approximately 13% 
of all deaths in Finland. Th e samples are analysed for a wide variety of drugs and approximately 
300 cases result in drug fi ndings annually. Th e selection of analysed drugs and medicines is 
frequently updated when new substances emerge. Toxicologists at the forensic laboratory 
performing the analyses actively search for information on new substances. In addition to the 
scientifi c literature, potential sources of useful information are the data provided by the Finnish 
Customs and Police, the European early warning system (EWS) and various international 
toxicology meetings.
In various countries over the years, probably the greatest number of deaths in which NPS 
were detected included mephedrone [172,173,174,175,176,31] or mephedrone together with 
other synthetic cathinones. In addition, methedrone, butylone, methylone, buphedrone para-
methoxymethylamphetamine (PMMA) and especially MDPV have been frequently detected 
in post-mortem cases [117,177,178,179,180,181,182, Table 2]. However, the post-mortem 
investigation process varies signifi cantly in diff erent countries; the range of drugs included in the 
screening procedures varies as does the nature of the samples analysed (Table 2). 
To date, the only population based study on drug-related deaths (DRD) involving NPS was 
published in 2014 by a Scottish group [117]. In their study, 36 cases with a NPS fi ndings were 
recorded in 2012 and in 23 of these, NPS were implicated in the actual cause of death [117].
Th e broad variety of NPS and the constantly changing selection of drugs to be analysed have 
created new challenges for post-mortem toxicology. Additionally, the lack of reference standards 
or their high cost may in some cases greatly delay the incorporation of new substances into the 
screening program. Th ese challenges have been addressed with novel analysis techniques such as 
HRMS [68].
In countries, such as Finland, where a considerable proportion of deaths undergo a medico-
legal cause-of-death investigation and toxicological analysis, recognizing the arrival of new 
drugs is easier than in countries with a lower rate of post-mortem toxicology. In Finland, nearly 
all drug-related death cases are likely to undergo post-mortem toxicology so the possibilities of 
detecting new trends in drug use patterns are high. Only aft er suffi  cient information on blood 
concentrations, clinical symptoms and drug use profi les of the NPS has been accumulated, can 
the toxicological information from post-mortem investigations be used in interpretation of the 
cases. 
2.7 Banning of NPS 
In Finland, NPS are regulated by the Narcotics Act [183]. Th e legal defi nition of a narcotic or 
psychotropic agent is set by the Finnish Narcotic Act and all banned substances are listed in the 
Government Decree (543/2008) [ 184]. Once a substance has been evaluated and is to be banned, 
it is added to the list in Government Decree (543/2008) [185].
Th e Finnish Medicines Agency, Fimea, proposes to the Ministry of Social Aff airs and Health 
which new substances should be classifi ed as narcotic drugs. Before being scheduled as narcotics, 
NPS are banned from the consumer market and listed in a separate Decree (1130/2014) [ 186]. 
Th e listing of an NPS as a substance banned from the consumer market is conducted aft er 
evaluating its pharmacological properties. Unlike with narcotic drugs, possession and use of 
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substances banned from the consumer market is not criminalised. Th ese substances are defi ned 
as those “used for intoxicating purposes that might be a danger to health and that have been 
decided to be made subject to control in accordance with the EU Council Decision or are 
positional isomers of such a substance and that are neither medicines nor narcotic drugs” [186].
 Th e procedure for evaluating substances proposed for listing as narcotic drugs is more 
thorough than that required for banning from the consumer market. In the process of scheduling 
NPS as narcotics, various characteristics of the substance or product are evaluated, including 
the pharmacological/toxicological properties, potential uses, exposure levels (concentration/
duration), information about potential users and risks associated with the substance. In 
most cases the process takes about 1-6 months and there is not always much evidence-based 
information available, which is typically the case for the NPS.
In Finland prior to June 2011, an NPS could not be added to Government Decree (543/2008) 
and brought under control of the Narcotics Act until similar action had been taken by the EU 
or UN. However, in June 2011 the Narcotics Act was modifi ed to allow the banning of an NPS 
in Finland without prior EU or UN action. Th is change should enable more rapid regulation, 
particularly in those cases in which a particular NPS presents a problem in Finland but not in 
other countries.
When evaluated retrospectively, banning decisions have been found to be mostly correct 
[187]. Banning of potentially benefi cial substances that may have medicinal use must be avoided 
while meeting the primary goal of reducing harm by keeping dangerous drugs out of the 
marketplace [188].
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3 AIMS OF THE STUDY
Th e aim of this study was to assess the prevalence, blood concentrations and signifi cance of 
selected new abused drugs in DUID cases and in post-mortem investigations in Finland and to 
characterise the toxicological profi le of users (I–V).
Th e more specifi c aims of the thesis were:
 To determine the prevalence and blood concentrations of 3,4-methylenedioxypyrovalerone 
(MDPV) and to investigate the concomitant use of other drugs in MDPV-positive DUID 
cases as well as the geographical distribution of the cases in Finland in a one year period 
between 28 August 2009 and the end of August 2010 (I) 
 To look at the same factors and issues in MDPV-positive DUID cases over a longer time 
span between August 2009 and December 2012 with additional information from post-
mortem cases in the same time period (V). 
 To use the data from psycho-physical assessments conducted aft er arrest to evaluate the 
signifi cance of the presence of MDPV (I).
 To investigate the police confi scations of NPS in order to gain information on the 
prevalence of MDPV (I).
 To determine the diff erences in blood concentrations, user profi les and concomitant use 
of other drugs in DUID and post-mortem cases before and aft er MDPV was banned, 
and to determine whether the impact on court decisions of fi nding MDPV in DUID 
cases changed aft er it was banned (V).
 To determine the prevalence, blood concentrations and signifi cance of phenazepam in 
drivers apprehended for DUID and in post-mortem blood samples in Finland and to 
assess the geographical distribution of the phenazepam-positive DUID cases in a one 
year period between July 1, 2010 and June 30, 2011 and to look at the police confi scations 
of the drug (II). 
 To determine the prevalence, blood concentrations and signifi cance of desoxypipradrol 
(2-DPMP) in drivers apprehended for DUID and in post-mortem cases in Finland 
between October 2010 and May 2012 and to look at the police confi scations of the drug 
(III). 
 To determine the blood concentrations of pregabalin in blood from DUID cases in 
Finland in a one year period in 2012, to assess the concomitant use of other drugs 
by drivers positive for pregabalin, and to re-evaluate the abuse potential of this drug 
formerly considered to be free of such problems, even when used by drug addicts (IV). 
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4 MATERIAL AND METHODS
Th e main focus of this thesis was the toxicology data from DUID investigations and post-mortem 
studies in Finland. Post-mortem and DUID toxicology data were compared with background 
data on the victims/culprits obtained from public records. Data on police confi scations of the 
studied drugs provided by the National Bureau of Investigation in Finland were also examined. 
Th e study period was 2009–2012. Further breakdown of the study periods, materials and 
registers used and number of cases studied in each of the fi ve studies presented in the original 
publications I–V are illustrated in Figure 7.
Figure 7. Timeline of the individual studies included in the thesis (I–V). Th e numbers in the boxes 
represent the size of the studied population/material. Th e numbers (N) on the right of the boxes are the 
number of cases studied in each part of the thesis (e.g. number of MDPV-positive samples in the studied 
population, or the number of separate court cases that included the 100 randomly selected DUID cases).
aOnly the clinical examinations of single-drug cases were examined.
Detailed descriptions of the materials, such as reagents and reference material used in specifi c 
parts of the study as well as method information and validation data are presented in the original 
publications (I–V).
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• DUID toxicology data 
(N=486) 
• Post-mortem  
toxicology data 
(N=38) 
• Helsinki District  
Court registry (N=78) 
1/2013 
• DUID toxicology data (N=106) 
• Post-mortem toxicology data (N=5) 
• Data on Police drug seizures 
• Clinical assessment of impairment (N=66) 
I: (9/2009-8/2010) 
New designer drug of abuse: 
3,4-Methylenedioxy-
pyrovalerone (MDPV). 
Findings from  
apprehended drivers in 
Finland 
3 000 selected DUID- 
cases  
II: (7/2010-6/2011) 
Phenazepam abuse in 
Finland: Findings from 
apprehended drivers, post-
mortem 
cases and police confiscations 
All DUID-cases (4 800) and all 
post-mortem cases (6 000) 
1/2011 1/2012 1/2010 
V: (9/2009-12/2012) 
The effect of banning MDPV on the incidence of MDPV-positive findings among users of illegal drugs and 
on court decisions in traffic cases in Finland 
Selected/all DUID-cases (13 500), all post-mortem cases (22 500) and selected court cases (100 ) 
III: (10/2010-5/2012) 
Prevalence and blood concentrations of 
desoxypipradrol (2-DPMP) in drivers suspected of  
driving under the influence of drugs and in post-
mortem cases. 
All DUID cases (6 465) and all post-mortem cases 
(11 000) 
IV: (year 2012) 
Pregabalin serum levels in 
apprehended drivers 
459 selected DUID cases 
• DUID toxicology data (N=259) 
• Data on Police drug seizures 
• Clinical assessment of impairment (N=207) 
• DUID toxicology data (N=141) 
• Post-mortem toxicology data (N=17) 
• Data on Police drug seizures 
• Clinical assessment of impairment (N=5)a 
• DUID toxicology data (N=206) 
• Clinical assessment of 
impairment (N=2)a 
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4.1 DUI inves  ga  ons
In the four-year study period between 2009 and 2012, the number of driving cases for which the 
police requested toxicological analysis ranged between 3863 and 4569 per year (Police statistics). 
All toxicological analyses for DUID investigations were performed in a single laboratory. Th e 
drug screening and confi rmation analysis procedures were designed by the Forensic laboratory of 
the National Bureau of Investigation in Finland in co-operation with the Offi  ce of the Prosecutor 
General. During the time period studied in this thesis the analytical procedure in DUI cases was 
as follows:
a. Driving while intoxicated –cases:
A comprehensive screening for abused drugs and medicines including amphetamines, 
cannabis, cocaine, benzodiazepines and opioids (also buprenorphine) was performed 
by immunological methods. Additionally, comprehensive screening (liquid 
chromatography – tandem mass spectrometry (LC-MS/MS) was performed for every 
sample to complement the immunological screening. Th e LC-MS/MS enabled high 
sensitivity screening for NPS in every sample, while the sensitivity of immunological 
methods for diff erent NPS is poor. All positive fi ndings were confi rmed by LC-MS/MS.
b. Driving while seriously intoxicated –cases:
In addition to the comprehensive screening (see above), screening for a selection of 
further illegal and medicinal drugs was conducted by means of gas chromatography – 
mass spectrometry (GC-MS) and LC-MS/MS.
Blood and serum samples were taken at the nearest health centre as soon as possible aft er the 
driver was apprehended. In cases of suspected heroin use, urine was also collected for the 
analysis of 6-acetylmorpine. In Finland, use of heroin has been extremely rare ever since the 
heroin shortage in Europe in 2001, which is why urine was only seldom collected in the study 
period (in less than 10% of the cases). Th e police offi  cers sent the blood and urine samples to 
the laboratory together with background information on the case. Th e police were instructed to 
store the samples in a refrigerator if it was not possible to mail them immediately.
All samples were delivered to the laboratory without identifying the driver. Samples were 
coded with 8 digit numbers. Th us it was not necessary to de-identify the samples before the 
study. Age and gender as well as time of the incident and time of blood sampling were recorded 
in the laboratory electronic record-keeping system. 
4.1.1 Road-side tes  ng of DUID suspects
In most cases, a driver is apprehended on suspicion of DUID because somebody reported them 
to the Police for unsafe driving or observed use of drugs or alcohol before driving. In some cases 
a driver may be apprehended because of a driving error that was observed by the Police. It is not 
common that suspicion of DUID would arise from a routine traffi  c stop check. 
Th e device most commonly used in road-side screening for drugs in the studied cases was 
DrugWipe 6s® by Securetec. Th e device consists of a miniaturised immunoassay that screens 
for amphetamines, cannabis, benzodiazepines, cocaine and opiates in oral fl uid. Th e device 
is operated by wiping the tongue or the inside of the cheek of the suspect. Aft er completing a 
simple processing procedure, the results are displayed aft er an 8 minute waiting period. 
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Regardless of the results of the roadside drug screening test, the driver could be held for 
further examination if there was reason to believe that they may have been under the infl uence 
of drugs. Th e results of the road-side screening test assist decision making by the arresting police 
offi  cer but they do not have evidentiary status so cannot be used in court.
4.1.2 Clinical assessment of driving impairment
Shortly aft er being caught, drivers suspected of DUID were subjected to a clinical assessment of 
impairment. Th is standardised examination was performed by a physician as per the guidelines 
provided by the Finnish Ministry of Social Aff airs and Health. Th e examination covered a total 
of 15 tests of motor, vestibular, and mental impairment. More details of the examination are 
given in paper III. Th e results of the clinical assessment – if performed – were used in the DUID 
investigation process in combination with the laboratory results and witness statements. 
4.1.3 Analy  cal methods
Th e analytical methods were validated according to the guidelines of German standard 
specifi cation DIN 32645 [189] and other guidelines for method validation in the forensic fi eld 
[190,191]. Details on method validations are presented in the original publications (I-IV) and in 
Table 3. Th e methods did not remain the same throughout the study period. Th ey were constantly 
developed to better meet the challenges of a massive sample load and strict timeframes of the 
DUID investigations. Moreover, new substances were regularly added to the methods when there 
was reason to believe that they were being used by Finnish drug users. However, the methods for 
the analysis of the substances in this thesis remained the same throughout the study periods (Fig. 
7), except for the MDPV method in DUID cases; at the beginning of the study period the MDPV 
methodology was a qualitative assay, but later, with the availability of commercial reference 
material, was further developed to be a fully validated quantitative method.
Sample preparation methods included solid phase extraction (SPE), protein precipitation 
(PP) with acetonitrile or liquid-liquid extraction (LLE). Th e method used for particular 
substances as well as the analytical methods are listed in Table 3. 
Th e drug screening procedure consisted of an immunological screening followed by a 
multi-analyte LC–MS/MS screening using multiple reaction monitoring (MRM). All samples 
underwent both screening procedures - a negative result from the immunoassay did not rule out 
LC-MS/MS screening. Most of the drugs frequently encountered were quantifi ed in the LC-MS/
MS screen but some required an extra quantifi cation step. However, apart from pregabalin, all 
analytes studied in this thesis were quantifi ed directly from the screening run. At the time of the 
study, pregabalin was only analysed when requested or when there was other reasons to believe 
that the driver had taken pregabalin (N=459, 12% of all DUID samples in the study period), and 
consequently the drug was quantifi ed by a separate method (Table 3).
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Table 3. Details of the analytical methods used for the analysis of the studied substances in the serum 










MDPV SPE LC-MS/MS 0.010 – 0.500 0.003 276126
276135
MDEA-d5d
Phenazepam SPE LC-MS/MS 0.003 – 0.100 0.0014 351206
351185
Diazepam-d5
2-DPMP SPE LC-MS/MS 0.003 – 0.500 0.003 25291
252167
MDPV-d8
Pregabalin PP LC-MS/MS 0.68 – 20.00 0.22 160142 2-amino-3-cyclo-
hexyl-1-propanol
alower limit of quantifi cation, bmonitored transitions in the MS/MS, cinternal standard, 
d3,4-methylenedioxy-N-ethylamphetamine, deuterated,
4.2 Post-mortem inves  ga  ons
All post-mortem samples in this study were analysed in one laboratory, namely in the toxicology 
laboratory of the Department of Forensic Medicine in the University of Helsinki. Th e analytical 
procedure for post-mortem samples is illustrated in Table 4.
Table 4. Th e analytical screening procedure of post-mortem samples applicable to this study.
Matrix Type of analysis Equipment Target compounds Reference
urine screening LC-TOFMS ~700 drugs 192,193
blood quantitative GC-NPDa acidic/neutral drugs 194
GC-ECDb benzodiazepines 195
GC-NPD basic drugs 196
blood/urine confi rmations CG-MS and LC-MS/MS
blood/urine quantitative HP-GC-FIDc alcohol
anitrogen-phosphorus detector, belectron capture detection, cheadspace gas chromatography with 
fl ame ionisation detection
For all of the studied substances in post-mortem cases, sample preparation included LLE 
followed by derivatisation of MDPV and 2-DPMP with heptafl uorobutyric anhydride (HFBA) 
and phenazepam with N-tert-Butyldimethylsilyl-N-methyltrifl uoroacetamide + 1 % tert-
butyldimethylchlorosilane (MTBSTFA + 1% TBDMSCl). Th e analytical parameters for the 
studied substances are listed in Table 5. All post-mortem blood results reported in this study 
originate from the analysis of femoral blood.
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MDPV EIa-GC-MS 0.02–2.00 0.02 126 149,121 MDPV-d8
Phenazepam CIb-GC-MS 0.005–0.40 0.005 312 314 Temazepam-d5
2-DPMP EI-GC-MS 0.01–5.00 0.01 280 165,226 MDMA-d5
aelectron ionisation, bchemical ionisation
4.3 Police confi sca  ons of NPS
Information on the number of samples of the studied substances in material confi scated during 
the studied time period was received from the Forensic Laboratory of the National Bureau of 
Investigations when requested. One confi scated sample can mean 2000 tablets or 1 gram of a 
substance so the numbers given for diff erent batches are not directly comparable but do provide 
a very rough estimate of the relative amounts of the drugs seized. 
4.4 Court sentences in DUID cases
Th e District Court in Helsinki is one of 27 in Finland. It serves a population of over 600 000 
inhabitants in the Capital of Finland and handles around 1800 DUID cases every year. 
Aft er receiving research permission from the Finnish Legal Register Centre, DUID case 
numbers and the numbers assigned to police reports of off ences were linked and a database 
search was conducted. From the database, 100 court cases positive for MDPV and located in 
Helsinki were randomly picked so that about half of the cases were from the time before MDPV 
was banned and the other half from the time aft er it. Th e randomness of the sampling was 
ensured in that the cases were picked from a list of numbers of MDPV-positive samples. Th ere 
was no other data on the cases in the list besides the numbers so that the person picking the 
cases did not know any details about the cases. Th us, the specifi cs of the cases, such as MDPV 
concentration, did not impact the selection of cases. Due to the relatively large sample size (100 
cases) and the random selection of court cases that were included in the study, the sample can be 
assumed to well represent the population of MDPV-positive apprehended drivers. Between 2009 
and 2012 there were 211 DUID cases positive for MDPV in Helsinki Police Department, thus the 
number of court cases selected for the study covers nearly half of the cases in the study period.
Th e selected cases were examined and scanned at the archive of the District Court of 
Helsinki. Age and gender as well as the number of charges and other details of the cases were 
recorded. Particular consideration was given to whether MDPV was mentioned in the court 
documents and reasoning.  
4.5 Sta  s  cal methods
All statistical analyses were performed using IBM SPSS soft ware (versions 18.0–20.0). For the 
comparisons, the Pearson Chi-Square test or the Fisher’s exact test were used for dichotomous 
variables, the independent-samples T test for continuous variables, and the Mann-Whitney, 




Analytical data, background information on the cases and information on the DUID incident 
without any personal identifi ers could be used for this register-based research without approval 
of the Ethical Committee. For the study that included court documents, research permission 
from the Finnish Legal Register Centre was obtained. Th e cases were coded and registered into a 
database according to the guidelines of the Finnish Legal Register Centre. 
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5 RESULTS AND DISCUSSION
In Finland, the yearly number of DUI investigations in which a blood sample is collected is over 
12 500. In approximately 4000 cases there is a drug request involved either alone or in addition 
to a request of alcohol analysis. In this thesis, the serum concentrations associated with abuse of 
selected NPS were studied; for some of the substances this is the fi rst time such data has been 
obtained. As can be seen from Table 2, previous data on blood concentrations associated with 
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d. PREGABALIN (N=206) 




















c. 2-DPMP (N=32) 
Figure 8. Concentration medians and percentile values for the studied substances (II–V). Th e dashed 
line (b. and d.) illustrates the upper limit of the therapeutic range. For 2-DPMP the maximum 
concentration is given instead of the 97.5th percentile since the number of cases with a quantitative 
result was too small for the calculation of the 97.5th percentile.
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abuse of these substances are for the most part anecdotal, based upon reports of single cases. 
Fig. 8 shows the results obtained from the individual studies in this theses in terms of median 
concentrations and the 90, 95 and 97.5 percentiles of the studied substances in serum. Since the 
number of cases positive for the studied substances in the study periods was not always the same 
as the number of cases for which quantitative results were obtained, the latter is given in Fig. 8 
next to the name of the substance.
As seen in Fig.8., the diff erences between median concentrations and the 97.5th percentile 
values were extremely large for all of the studied substances but especially for MDPV indicating 
that there were some very high concentrations included in the data. Th e fact that some 
individuals were able to drive, or at least thought they could drive, with such high concentrations 
of MDPV in their system is probably due to the development of tolerance to the pharmacological 
eff ects of the stimulant [151]. Similarly, in Sweden, blood amphetamine concentrations as high 
as 5–17 mg/L have been reported in drivers [197] even though such concentrations are normally 
associated with fatal intoxications.
In general, the use of many medicinal drugs is concentrated in older age groups whereas 
drug abuse is more prevalent among younger individuals. Th e age and gender distribution of the 
studied substances in DUID cases and the age distribution in all Finnish DUI cases in 2012 is 
illustrated in Fig. 9. 
Figure 9. Age and gender distribution of MDPV, phenazepam, 2-DPMP and pregabalin in the study 
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As seen in Fig. 9., females were proportionally much more represented in pregabalin-positive 
cases (41%) than in cases positive for other studied substances (11–15%) (p<0.001) [VI]. 
Moreover, there were proportionally more women in younger age groups (under 35 years) of 
all studied substances than in older age groups [VI]. None of the substances were frequently 
encountered in individuals aged 60 or older. Th e mean ages of drivers positive for each of the 
studied substances are illustrated in table 6.
Table 6. Mean ages of the drivers positive for the studied substances and the statistical signifi cances of 
the age diff erences between genders (II–V).
 
Mean age Signifi cance
of the age diff erence Refmales females
MDPV 36 33 p<0.012, t test V
Phenazepam 34 27 n.s. II
2-DPMP 35 31 n.s. III
Pregabalin 33 32 n.s. VI
Th e frequency distributions of the studied substances in diff erent age groups as illustrated in Fig 
9. resemble that of drug users in general in that the highest numbers of cases are in younger age 
groups except for phenazepam, the profi le of which is two-peaked resembling the profi le of drivers 
positive for alcohol (Fig. 9e). An explanation for the diff erent profi le for phenazepam could not 
be deduced from the study material nor from earlier literature. In terms of age diff erences in 
drug use patterns, previous studies have shown that whilst young individuals may experience the 
rewarding properties of drugs more strongly than older individuals, their sensitivity towards the 
adverse eff ects of drugs may be attenuated, which may increase the probability of continuing the 
use aft er the fi rst experiences [198]. 
5.1 MDPV
5.1.1 MDPV-posi  ve DUID cases in the early stage of its appearance in 
Finland
In this thesis, MDPV was studied twice. In the fi rst part (I), MDPV-positive cases in the DUID 
population were assessed at an early stage of its appearance in the illegal drug market. At the 
time, awareness of NPS in general was not widespread and many health care professionals did 
not know that they existed. MDPV was the fi rst designer drug that gained widespread publicity 
in Finland, largely because it was connected to some brutal crimes, including homicides. 
In 2009 and 2010, MDPV was frequently detected in DUID suspects in Finland. Nearly 6% 
(N = 259) of all positive DUID cases in the one-year study period were positive for MDPV (I). 
Th e main contribution of study I to toxicological knowledge was the fi rst publication of serum 
concentrations associated with abuse of MDPV. Th e large number of cases in this study provided 
exceptional material for that purpose. At the beginning of the study period, only a qualitative 
assay for MDPV was available, thus quantitative results are only available for a subgroup of 
the samples. Th e concentration of MDPV ranged between 0.016 mg/L and 8.4 mg/L (median 
0.22 mg/L) (I). Th e median concentration is markedly higher than reported in a very recent 
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Australian study on 33 MDPV-positive drivers (0.05 mg/kg) [81]. When compared to a Swedish 
study with over 26 000 driving cases, the median MDPV concentration in the present study was 
higher than that of MDMA (0.10 mg/L) but lower than the median amphetamine concentration 
(0.70 mg/L) in the Swedish material [199]. 
Most of the MDPV-positive drivers were male (87%) and the majority was aged between 25 
and 44 years (76%) (I). 
In most cases (96.9%), MDPV was found together with other potentially impairing 
psychoactive substances; most oft en amphetamine (80%) or benzodiazepines (67%) or both 
(54%) (I). It appeared that the blood levels of sedatives used together with MDPV were relatively 
low when compared to DUID cases without MDPV use. In contrast, concentrations of other 
stimulants used together with MDPV were high. Alcohol was only rarely found in MDPV-
positive cases, and mainly in very low concentrations (I).
5.1.2 DUID and post-mortem cases posi  ve for MDPV over a 3½ year 
period
In the second study related to MDPV (V), a longer time period (about three and a half years) was 
investigated as well as the post-mortem cases positive for MDPV in the same time period. In this 
study, the number of MDPV-positive DUID cases was 486 and the number of MDPV-positive 
autopsy cases was 38. Th e median serum concentration of MDPV in DUID cases was 0.030 mg/L 
and in post-mortem cases 0.12 mg/L (V). 
In the study period, 86% and 79% of the cases were males in DUID and post-mortem 
cases, respectively. In DUID cases, women were signifi cantly younger (mean 33.2 years) than 
men (36.1 years). In post-mortem cases the age diff erence between the two genders was even 
more prominent (women 24.3 vs. men 35.9 years). Additionally, the average age reported for 
MDPV-positive female fatalities was considerably lower (24.3 years) than the average age of all 
fatal poisonings of users of illicit drugs (both genders, all drugs) in Finland in 2012 (33.2 years) 
[11] (V). 
In the majority of cases, MDPV was detected together with various other drugs. It was the 
only drug found in only one post-mortem investigation and in only 4% (N=20) of the MDPV-
positive DUID cases. In 22% of the MDPV-positive DUID and 42% of the MDPV-positive post-
mortem cases, MDPV was the only stimulant detected. In MDPV-positive DUID cases, males 
had an average of 4.2 other drugs present besides MDPV whereas the number in females was 
3.6 (p=0.018). In MDPV-positive post-mortem cases the mean number of other drugs was 4.5. 
Amphetamine (DUID 75%, post-mortem 58%), benzodiazepines (DUID 74%, post-mortem 
71%), cannabis (DUID 28%, post-mortem 24%) and opioids (DUID 13%, post-mortem 68%) 
were frequently encountered in both MDPV-positive DUID and MDPV-positive post-mortem 
populations. In DUID cases, the number of other drugs used together with MDPV decreased 
slightly with age (p<0.001 Spearman’s rho) (V). MDPV was oft en encountered together with 
other NPS, e.g. 2-DPMP, methylone and synthetic cannabinoids. Some of these fi ndings may be 
due to the substances being sold as mixtures (V).
It is quite remarkable that alcohol was present only in 1.6% of the MDPV-positive DUID 
cases (N=8). However, alcohol was not analysed in every sample, but only when the police 
had requested it, meaning that in some cases alcohol may have been present but not analysed. 
In post-mortem cases, however, alcohol was analysed in every sample and the percentage 
of alcohol-positive MDPV-positive cases, 21% (N=8), was closer to the rate reported for fatal 
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poisonings of users of illicit drugs in Finland in general (36.4%) [11]. Nevertheless, even if all 
MDPV-positive DUID samples had been screened for alcohol, given that the drug use profi le 
was quite diff erent between MDPV-positive DUID and MDPV-positive post-mortem cases in 
respect to CNS sedatives such as opioids (V), it is unlikely that alcohol use would be the same in 
the two populations.
Of the 38 deaths in the study period involving MDPV, 28 were determined by the forensic 
pathologist to be fatal poisonings. Of these, two were poisonings by MDPV only and the other 
14 were multi-drug poisonings with MDPV together with other drugs. Th e remaining 12 
poisonings included poisonings with propranolol, doxepin, opioids and carbon monoxide and 
in these MDPV was considered purely an incidental fi nding. Th e manner of death and cause 
of death are further illustrated in Fig. 10. which shows that the majority (92.1%) of the MDPV-
positive individuals in the post-mortem material died of unnatural causes (V).
Figure 10. Frequency of diff erent causes of death in the four death classes for 
deceased positive for MDPV in the study period in Finland (2009–2012) (V).
Suicide was more prevalent among those post-mortem cases positive for MDPV than among 
fatal poisonings of users of illicit drugs in general (24% vs. 6%) [11]. MDPV-positive suicide 
victims were also signifi cantly younger than those MDPV-positive individuals who died of other 
causes (28.3 vs. 35.3 years, p=0.039, t-test). Previous research on suicide victims has revealed 
that drug users who have attempted suicide are indeed younger than drug users who have never 
attempted suicide [200]. Since the vast majority of the deceased in the study material had several 
other psychoactive substances besides MDPV in their system, it is impossible to estimate the 
role of MDPV in these cases. In only one of the suicides, was the victim known to have taken 
MDPV (among other substances) in order to commit the act. In other studies, cathinones have 
been found to be highly prevalent in suicides [84], which may suggest that the substances possess 
properties that induce suicidal thoughts (V).
5.1.3 Clinical assessment of impairment in MDPV-posi  ve cases
In the clinical assessment of driving impairment, some of the MDPV-positive drivers did 
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overall psychomotor performance was found to be within the normal range, some functional 
impairment was detected in 84% of the MDPV-positive cases. Th e most prevalent aberrations 
detected in the examination included diffi  culty in defi ning the current time, walking on a straight 
line, turning around, and speech, which all are symptoms that have been observed in association 
with the use of synthetic cathinones [78]. In this study, however, it was not possible to determine 
to what degree these aberrations were due to MDPV since the drug was is most cases found 
together with a variety of other psychoactive drugs. Another problem in the study material was 
that the clinical assessment of impairment was not performed in every case, even though it is 
legally required in all cases of suspected DUID (I). 
5.1.4 Police confi sca  ons of MDPV
Th e analysis of confi scated MDPV samples revealed that MDPV and phenazepam were 
sometimes sold as a mixture. Th e Finnish Police confi scated 219 batches of MDPV in the one-
year study period (between 28 August 2009 and the end of August 2010). At the time, MDPV 
accounted for 45% of all confi scations of NPS and was the most prevalent NPS among all 
confi scated substances. Th e confi scated MDPV samples were found to originate in China (I).
5.1.5 MDPV before and a  er it was banned
Th e incidence of MDPV both in DUID and in post-mortem investigations decreased aft er it 
was banned (V). In DUID cases the decrease in the mean monthly numbers was 51.1%. Aft er 
banning, the numbers of DUID cases positive for MDPV stabilised at a level of 5 to 10 cases 
per month. In post-mortem investigations, MDPV-positive cases became quite sporadic aft er the 
banning (V).
Th e multi-drug use pattern in the MDPV-positive DUID cases changed to some extent aft er 
MDPV was banned. Th e percentages of drugs used together with MDPV before and aft er the 
banning are illustrated in Fig. 11.
Figure 11. Other fi ndings in MDPV-positive drivers before and aft er 






























When looking at the toxicology fi ndings of the DUID drivers in court cases before and aft er the 
banning of MDPV, a change was observed in that amphetamines and opiods were signifi cantly 
more oft en found together with MDPV before it was banned than aft er it (Fig. 11) (p<0.02, 
Fisher’s exact test). Th is fi nding is, however, somewhat skewed due to the fact that before it was 
banned MDPV was not screened for in every sample but it was aft er banning. Assuming that the 
observed change in the concomitant use of other drugs aft er the banning was real and not just 
a refl ection of diff erences in study populations, this could suggest a change of user population 
over time. Th e temporal evolution in the use of NPS seems to be from initial use by established 
drug abusers, who frequently inject amphetamine and/or opioids, then expanding into a larger 
population of experimenters who less frequently use amphetamines and/or opioids. Th is 
temporal evolution in the user population for NPS could explain the results of an Australian 
study in which a geographic shift  of MDPV use was observed over time from high population 
density areas, where i.v. use of illicit drugs tends to be concentrated, towards detections of 
MDPV over a wider geographic are with lower population density, where i.v. drug users are less 
prevalent [81] (V).
5.1.6 MDPV in court cases
In order to see what had changed aft er MDPV was banned in terms of how the court discussed 
MDPV fi ndings in the DUID cases that went to court, certain demographic characteristics of 
the defendants were investigated (V). Th e percentage of MDPV-positive defendants that were 
male rose from 76.7% to 93.2% aft er the banning. Th e mean number of charges (DUID and 
others) remained the same throughout the study period. Banning of MDPV had no eff ect on the 
percentage of MDPV-positive defendants without a fi xed abode, which was high throughout the 
study period (around 37%) (V). 
Before it was banned, MDPV was only mentioned in the court decisions of 4.7% of the 
MDPV-positive DUID cases whereas aft er the banning it was mentioned in 95.5% of MDPV-
positive DUID cases. Th is is likely related to the legal system in Finland where, in cases in 
which the basis of the charge is the fi nding of substances categorized as “zero-tolerance drugs” 
(banned substances), the drugs must be identifi ed in the documents reporting the court’s 
decision. However, if the basis of the DUID court case is impairment, rather than the presence 
of a psychoactive substance (either banned or not banned), the court is not required to name 
the substance that caused the impairment but rather discuss the observations that demonstrate 
impairment. Th e high percentage of cases in which MDPV fi ndings were mentioned in the 
court documents aft er it was banned are therefore not surprising since the fi nding of a zero 
tolerance substance is a stronger basis for prosecution than demonstrating driving impairment. 
Th e low percentage of cases in which MDPV fi ndings were mentioned in the court documents 
before it was banned is disappointing given the eff ort that was made to provide the court with 
information in the statements of laboratory results that gave a realistic view of the probable 
negative impact of MDPV on driving performance. However, in the vast majority of the cases 
the court did not need the MDPV fi nding for the sentence since other already illegal drugs were 
present in addition to MDPV, enabling a direct conviction based on the zero-tolerance law (V). It 
is thus understandable that, before MDPV was banned, the court did not care to use the MDPV 
fi ndings and perhaps complicate the prosecution.
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5.1.7 Geographical distribu  on of MDPV
Th e results of this thesis  are generally in good accordance with earlier studies in that the vast 
majority of all MDPV-positive DUID cases in the 4-year study period were from urban areas 
(Fig. 12) [ VI,201]. However, while study VI found the majority of MDPV-positive DUID cases in 
the greater Helsinki urban area, two independent studies of community wastewaters carried out 
in 2012 in several cities around Finland, found that MDPV was most prevalent in cities in eastern 
Finland close to the Russian border [111,112]. A greater volume of traffi  c and DUI surveillance 
may explain the concentration of MDPV-positive DUID cases in Helsinki. and suggests that the 
distribution of DUID cases will not necessarily indicate the overall distribution of users since it 
does not include those who do not drive while intoxicated or do not get caught.
Figure 12. Geographical distribution of MDPV-positive cases in DUID investigations calculated as 
cases per 10 000 inhabitants [VI].
In this study the prevalence of MDPV was highest in the capital area during all years of the study, 
but in the year of the wastewater studies (2012), a major shift  could be seen in case numbers from 
Helsinki towards eastern Finland (Fig. 12.) [VI]. Th e expanding geographical distribution can to 
some extent be due to the increased awareness and availability of the drug with time but that 
does not explain the very local popularity of MDPV at the eastern border. Th e more plausible 
explanation could be that the delivery routes to Finland may have been from Russia and that 
MDPV was thus readily available close to the border.
5.2 Phenazepam
In the one-year study period of the second part of this thesis, Phenazepam was screened in 
every sample from the apprehended drivers and was found in 141 (35%), which is a very high 
rate considering the illegality of the substance (II). Besides Finland, phenazepam has been 
frequently detected in the UK and Norway [117,202]. A considerable portion of phenazepam-
positive drivers (29%) were apprehended in the South Karelia Police district which is an area 
in south-eastern Finland next to the Russian border (II). Phenazepam used in Finland is 
believed to originate mainly from Russia and the geographical distribution of the phenazepam-
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not denoted in the background material received by the laboratory, some of the phenazepam-
positive cases may be Russian drivers with a valid prescription for phenazepam. Unfortunately, 
no geographical distribution data from wastewaters in Finland is available for phenazepam since 
the two studies conducted recently did not include benzodiazepines [111,112].
Th e concentration of phenazepam in DUID cases was oft en high suggesting abuse of the 
drug. Th e median (range) phenazepam serum concentration in DUID cases was 0.061 mg/L 
(0.004–3.600 mg/L), which is lower than in a report on drivers from Georgia, US (0.17 mg/L) 
[89] but similar to a single case report from Houston, US 0.076 mg/L [88]. In nearly 50% of the 
cases in the study material, the concentration of phenazepam was above 0.070 mg/L which is the 
upper limit of the suggested therapeutic range in the treatment of anxiety [73]. Th e mean (range) 
age of all phenazepam-positive drivers was 33.1 (18–61) years and most of them (88%) were 
males (II).
In drivers, phenazepam was oft en found together with other benzodiazepines (43.3%) or 
amphetamine (67.4%) or with both (29.1%). Th e concentration of phenazepam was signifi cantly 
higher in cases where there was no concomitant stimulant use (median 0.215 mg/L) when 
compared to the overall material. Th is is analogous to the MDPV fi ndings where MDPV 
concentrations were higher in those cases in which no other stimulant was found. In only 7 cases 
was phenazepam the only psychoactive substance found in the blood of the driver (II). 
In the course of this study, urine samples delivered together with the serum samples in some 
of the DUID cases (N=23) were analysed in addition to the serum samples. Th e active metabolite 
of phenazepam, 3-hydroxyphenazepam (OH-phenazepam) was the main substance in urine but 
the parent substance was also present in most cases, albeit in much lower concentrations (II). 
In post-mortem investigations, phenazepam was screened in every sample and found 
in 17 autopsy cases in the study period. Phenazepam was in most cases found together with 
opioids (70.6%) and alcohol was also very oft en present (52.9%) (II). Benzodiazepines (and ethyl 
alcohol) combined with opioid use have been shown to markedly increase the risk of fatality by 
enhancing the respiratory depression caused by opioids [203]. 
In the studied post-mortem cases, phenazepam was never the primary cause of death, 
which is consistent with the general situation with other benzodiazepines. Th e median (range) 
phenazepam blood concentration in the post-mortem cases was 0.048 mg/L (0.007–1.600 mg/L) 
which is lower than in an earlier study of 20 Finnish post-mortem cases (0.09 mg/L) [204] 
(II). Th e median concentration in drivers was higher than in fatalities and also higher than 
the concentrations reported in fatalities in other studies [80,93]. Because of the low toxicity of 
phenazepam alone, other concomitant substances, typically intravenous opioids, are needed for 
a fatal outcome. Th e low concentrations found in phenazepam post-mortem cases may be an 
indication that it can potentiate the lethal eff ect of opioids even at lower concentrations.
In most phenazepam-positive cases in the post-mortem material, the cause of death was 
determined by the forensic pathologist to be accidental overdose with one or several psychoactive 
substances. Phenazepam was implicated in the death, together with other substances, in fi ve 
cases out of the 10 fatal phenazepam-positive poisonings [VI]. All of the phenazepam-positive 
deceased were male and the mean age was 35 years. Just as in traffi  c cases, nearly two thirds 
of the fatalities with a positive phenazepam fi nding occurred in Eastern Finland close to the 
Russian border (II).
Phenazepam constituted 0.2% of the number of samples in police confi scations. Th e samples 
consisted mainly of tablets, capsules and powder, but also some fl uids were found. Unlike the 
geographic distribution of phenazepam-positive traffi  c cases and fatalities described above, most 
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of the phenazepam was confi scated in Helsinki, while the South Karelia Police Department, close 
to Russian border, made up 23% of the confi scations (II).
5.3 Desoxypipradrol
Triggered by reports of cases of severe intoxication of young adults by an originally unknown 
designer drug, the screening of DUID samples for desoxypipradrol (2-DPMP) was initiated in 
2010. In this study (III), DUID and post-mortem cases positive for 2-DPMP were investigated 
in a period of about 1.5 years between 2010 and 2012. In the study period, 106 (1.7%) of the 
confi rmed DUID cases were positive for 2-DPMP. Th e monthly numbers were highest right aft er 
the start of the screening for the drug, which suggests that some drivers had assumed it would not 
yet be detected in the analysis of blood samples. In post-mortem investigations the percentage 
of cases positive for 2-DPMP was 0.05%; only 5 positive cases were detected in the study period. 
Th e median (range) 2-DPMP serum concentration in DUI cases was 0.065 (0.006–0.480) mg/L 
and in post-mortem blood 0.72 (0.01–1.4) mg/L (III). 
Again, most of the drivers positive for 2-DPMP were males (85.5%). Th e mean age of 
2-DPMP-positive drivers was 34.1 years (III). 
Both in DUID and post-mortem cases, 2-DPMP was always detected together with 
various other psychoactive substances. In DUI cases the most prevalent co-fi ndings were other 
stimulants (87.9%) or benzodiazepines (82.1%) or both (62.3%). Alcohol was present only in 
2.8% (N=3) of the cases. In 19.8% of the DUID cases positive for 2-DPMP, the driver had also 
taken MDPV (III).
In all of the post-mortem cases, 2-DPMP was detected with other psychoactive substances. 
Opioids were present in most cases but alcohol in none. 2-DPMP was estimated by the forensic 
pathologist to have contributed to the death in two of the fi ve 2-DPMP-positive post-mortem 
cases. In both of these, opioids were also present. Th e post-mortem blood concentration in both 
of these cases was 1.4 mg/L which is more than 20 times higher than the median 2-DPMP serum 
concentration in DUID cases (III).
Additionally, the results of the clinical examinations performed by a physician shortly 
aft er the arrest of the suspected driver were examined. Th e clinical examination for driving 
impairment was conducted in 57 of the 106 cases positive for 2-DPMP. Of these 57 examinations, 
psychomotor aberrations were observed in 69.7%. Th e most frequent aberrations included mood 
alterations, delayed/reduced pupil reaction to light, behavioural changes, problems in walking 
on a straight line and speech. However, on the three-step scale available for the physician for 
the assessment of the overall impact of these aberrations on the psychomotor performance of 
the suspect, only 39.4% of the drivers examined were judged as having been impaired while 
examined (III). 
In a previous study of apprehended drivers in Germany, one of the subjects was found to 
be positive for 2-DPMP with a concentration of 0.36 mg/L which is at the upper end of the 
concentration range described in this thesis (III). Th e driver was assessed as showing signs 
of being under the infl uence of drugs by an examining physician and claimed to have had an 
episode of micro-sleep resulting in the car straying from the road and turning over. In addition 
to 2-DPMP, she had also a low concentration of MPDV and traces of benzedrone in her blood, 




Pregabalin was studied in DUID cases in 2012 over a period of one year (IV) in which a total of 
459 samples (12% of all samples) were screened for the drug. Th ere were 206 positive cases with 
median (range) serum concentration of 6.2 (0.68–111.6) mg/L which is in the upper third of the 
suggested therapeutic range (2–8 mg/L). Th e majority of the samples were above the upper limit 
of the typical therapeutic range. Th e highest concentrations in this study were well beyond the 
levels seen in fatalities [205, Table 2]. In DUID cases, pregabalin was unfortunately not analysed 
from every sample at the time of the study, but only when requested by the police or when the 
background information suggested use of pregabalin. Th us no assessments can be made of the 
prevalence of pregabalin from these numbers (IV).
Similarly to the other studied substances, in pregabalin-positive cases the concomitant 
use of other psychoactive drugs was extremely common. Th e mean number of other drugs in 
pregabalin-positive cases was 4.3, the highest number being 9. Some individuals may use several 
diff erent drugs simultaneously under medical supervision in an appropriate manner. However, 
many of the DUI suspects in the study material showed concomitant use of pregabalin with 
illegal drugs, or pregabalin and a combination of other medicinal drugs that generally should 
not be used together, such as several diff erent benzodiazepines or opioids. Of the pregabalin-
positive drivers, 54.4% also had cannabis and 44.2% had amphetamine in their blood (IV). Th ese 
fi ndings are in good accordance with previous research on pregabalin in Finnish post-mortem 
samples where 48% of the pregabalin-positive cases were considered to be drug abuse rather 
than appropriate medical use [98]. 
Th e percentage of women in the DUID cases positive for pregabalin (20%) was higher 
than the percentage of women positive for the other drugs detected in apprehended drivers in 
this thesis. Th is could be because some portion of the pregabalin fi ndings in women was due 
to appropriate medical use since, in earlier studies, consumption rates of prescription drugs in 
general have been shown to be higher for women than for men whereas the frequency of illicit 
use of prescription drugs is equal for both genders [206]. In this study, the percentage of female 
drivers that had, in addition to pregabalin, either amphetamines or cannabis in their blood was 
almost equal to that of males (29.3% vs. 29.7%) (IV). 
Of the 206 cases positive for pregabalin in the study period, in three cases pregabalin 
was the only psycho-active drug detected. Th e concentrations in these cases were 17.9 mg/L, 
18.2 mg/L and 0.7 mg/L. In one of the cases with a high concentration (17.9 mg/L) a clinical 
examination of impairment was performed and aberrations were found in walking on a straight 
line and pupil reaction to light. However, the overall psychomotor performance was considered 
by the examining physician to be within the normal range (IV). Th e only of previous research 
on pregabalin and driving impairment involved driving simulator studies with low drug doses 
[136,137]. Based on pharmacokinetic data for pregabalin, the driving simulator study which 
used the higher dose (150 mg t.i.d.) would result in an average blood concentration of 1.27 mg/L 
(range: 0.29–2.84 mg/L) which is at the lower end of the typical therapeutic range [171]. Th erefore 
the information from these driving simulator studies is of limited use when considering possible 
impairment in the cases with very high blood concentrations described in this thesis.
Some users have reported feelings of euphoria with pregabalin [134,135,207], which may 
explain the otherwise inexplicable abuse of this drug. Th e results of this study provide further 
evidence that many users of illegal drugs also abuse pregabalin. 
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5.5 NPS in post-mortem cases
New substances were added to the toxicological screening program for post-mortem cases 
whenever there was reason to believe that a certain substance could be being abused in Finland 
and if there was a reference standard available for the substance. For some substances, confi scated 
material from Customs or the Police was used as reference material until commercial reference 
standards became available. NPS fi ndings in post-mortem cases from 2009 to 2012 are illustrated 
in Fig. 13. Th e total number of fi ndings in this time period was 95 in 75 separate cases [VI]. 
Phenazepam and pregabalin are not included in these numbers. Unfortunately, the dates when 
they were fi rst included in the screening program are no longer available for all substances in Fig. 
13., but they were included as soon as there was any indication of their abuse in Finland.  It is 
thus likely that very few cases positive for these NPS were not detected in the study period.
Figure 13. Number of NPS fi ndings in post-mortem investigations in 2009-2012 
(excl. phenazepam and pregabalin) [VI].
As can be seen from Fig. 13., synthetic cannabinoids are almost completely absent from the post-
mortem statistics in Finland even though they have been included in the analytical methods since 
2009. JWH-018 and AM-2201 were both from one case which was also positive for 4’-methyl-
α-pyrrolidinopropiophenone (MePPP) [VI]. In other countries synthetic cannabinoids have 
been occasionally detected in post-mortem samples [208,209,210,211]. Th e EMCDDA annual 
report on NPS lists synthetic cannabinoids as the single biggest group of emerging substances 
in the last 3 years and the group has grown every year more than other drug groups [9]. Despite 
this, however, they have not appeared more frequently in the post-mortem statistics in Finland 
suggesting either lower toxicity of the substances when compared to that of other NPS, e.g. 
synthetic cathinones, or, that the prevalence of the use of synthetic cannabinoids is lower in 
Finland than in other countries. In drug-related death cases in Finland, the main intoxicant has 




































Of the deceased positive for any of the NPS in the study period, 78.7% were males. Mean 
(range) age was 33 (17–63) years. For most, the manner of death was determined by the forensic 
pathologist to be accident (60.0%) (including accidental overdose), which is in accordance with 
previous research on users of illicit drugs [ 212,213]. Th e frequency of other manners and causes 
of death, using the categories defi ned by Finnish forensic pathologists, are illustrated in Fig. 14. 
Th e cause of death was in most cases (64.0%) fatal poisoning by illegal or medicinal drugs and in 
most of these cases (58.3%) one or several NPS were mentioned as having directly contributed to 
the death. Of these 75 deaths, 88.0% were assessed to be deaths by unnatural causes [VI].
Figure 14. Frequency of diff erent causes of death (fatal poisoning, fatal injury, other) for each of the 
fi ve manners of death for deceased positive for any NPS in the study period in Finland (2009–2012) 
(phenazepam and pregabalin excluded) [VI].
Th ere were three fatal traffi  c accidents in the study period in which NPS were present [VI]. Two 
of the victims had been driving motorcycles and one was the driver of a car. MDPV was present 
in two of the cases (0.07 and 0.059 mg/L), in the latter case together with alpha-PVP (0.6 mg/L). 
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Driving under the infl uence of alcohol and drugs presents a serious risk to everybody on the 
road. According to EMCDDA, alcohol is involved in about 25% of the traffi  c accidents in Europe 
but the role of drugs in traffi  c accidents is harder to estimate due to the limited amount of 
data available [214]. NPS constitute a new and worrisome threat to traffi  c safety although the 
magnitude of that threat is poorly understood since information on their prevalence and impact 
on driving ability is limited. In this thesis, new information on NPS was obtained from DUID 
and post-mortem investigations and from DUID court cases. 
Th e toxicology results from DUID investigations proved to be excellent material for studying 
prevalence and user profi les of NPS since all of the studied substances were frequently detected 
and thus a large body of results was available for examination. Post-mortem investigations also 
provided data, albeit with a substantially lower number of cases. Police confi scations, results 
from clinical impairment tests on apprehended drivers and court documents on DUID cases also 
contributed to the data. 
One of the main goals of this study was to obtain additional information on prevalence and 
blood concentrations of NPS to supplement the very limited amount already available. Before 
the initiation of the study, the appearance of MDPV in Finland in particular had been widely 
reported in the news and had been the subject of much discussion. Despite this public interest, the 
true prevalence of NPS use was unknown. Among the fi ndings of the study, the high prevalence 
of 2-DPMP in Finland was especially unexpected since the international prevalence of 2-DPMP 
was – and still is – quite limited. Phenazepam, on the other hand, had been present in Finland 
for a long time but at the time of the study it was not yet banned. Th e magnitude of the impact 
of phenazepam use on driving safety in Finland may have been underestimated earlier since the 
extent of its use was not generally known. In the case of pregabalin, a number of reports on its 
abuse potential had been published by the time this study was initiated [97,127,128,215,216] but 
little information was available on the eff ects of pregabalin on driving performance [136,137] or 
on the concentrations associated with abuse of the drug (Table 2). Th is situation prompted its 
inclusion in the examination of fi ndings in DUID suspects. Th e DUID and post-mortem cases 
studied in this thesis proved to be an outstanding material with which to expand understanding 
of the toxicology profi le of the selected NPS at the time when the problems their abuse creates 
were being increasingly recognised.
6.1 Analy  cal aspects and methodological considera  ons
Th e problems and questions faced in the toxicological analyses of DUID investigations all 
over the world are for the most part alike. Th e lack of scientifi c information on NPS and lack 
of commercially available reference standards greatly complicate screening NPS in human 
samples. Th e International Council on Alcohol, Drugs and Traffi  c Safety (ICADTS) guidelines 
for research on DUID recommends that every driver be screened for the same panel of drugs. 
Th e analytical approach applied in the individual DUID studies in this thesis was not completely 
in accordance with this guideline since it was not designed for research purposes but rather for 
routine investigation of more than ten thousand cases every year. In order to meet the needs of 
the police and best support any prosecutions arising from the cases, the range of drugs screened 
was largely determined by the nature of the preliminary charges fi led by the police [217]. Th e 
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practice adopted was a compromise between ensuring an effi  cient process while including a 
reasonable spectrum of abused, illicit and licit drugs.
Th e analysis of DUID and post-mortem samples was performed in two separate 
laboratories utilising somewhat diff erent analytical approaches. Both laboratories had, however, 
acknowledged the pitfalls of immunological screening of drugs in forensic toxicology and 
proceeded to comprehensive target screening with MS-based methods. For the analysis of post-
mortem samples, and especially in cases of fatal intoxication where every fi nding may be relevant, 
the LC-TOFMS screening has proved very useful. Of the NPS-positive post-mortem cases in the 
study period, one or several NPS were implicated to the death in more than half of the cases [VI].
Th e study periods in the individual studies included in this thesis were in most cases 
selected in such a manner that the substance in question was analysed from every sample in the 
study period. Th is was true for all post-mortem investigations. In the DUID investigations there 
were, however, two exceptions. (1) At the beginning of the fi rst study period (2009), MDPV was 
not analysed from every sample but only in cases where there were amphetamines present in the 
sample or there was otherwise reason to believe that the person had taken MDPV (I). It is likely 
that few (if any) MDPV-positive samples were not analysed since later, when the process was 
changed so that every sample was screened for MDPV (2010), the majority of MDPV-positive 
samples also had amphetamines present (I,V). (2) For the whole study period of the pregabalin 
study (2012), pregabalin was only analysed when requested by the Police. At the time, pregabalin 
was studied from 12% of all samples. It is likely that many pregabalin-positive cases were missed 
and thus no estimates on the prevalence of the drug could be made. 
It is reasonable to assume that not all individuals driving under the infl uence of drugs in 
Finland are apprehended. Suspected DUI drivers are in many cases apprehended due to fellow 
citizens’ reports on unsafe driving or observed use of intoxicants before driving. Driving errors 
observed by the Police are also common reasons behind the apprehension. It is, however, not 
particularly common to catch a drugged driver in random stop checks. Th us it is likely that at 
least those drivers that are seriously impaired by the use of drugs will be caught in this system. 
Drug users that do not have access to a motor vehicle or are so intoxicated that they cannot even 
enter a car are not included in the DUID material used in this thesis. 
In forensic post-mortem investigations in Finland, all unexpected deaths are autopsied and 
in most cases also examined toxicologically. It is likely, that very close to 100% of all drug related 
deaths undergo a thorough post-mortem toxicological analysis in Finland. Th us the coverage of 
the post-mortem material is excellent for research on drug prevalence and toxicity. 
6.2 Clinical impairment tes  ng in DUID-cases
Many policemen are extremely skilled in detecting drug use in a driver, as indicated by the fact 
that over 90% of the samples sent to laboratory analysis are positive for at least one psychoactive 
substance (police statistics from 2012). Th e roadside screening test mostly used in Finland 
(DrugWipe®) has been shown to perform well in cases of amphetamine use but to a somewhat 
lesser degree with e.g. opiates or cocaine [141,218]. Th e clinical tests performed aft er the arrest 
in many of the studied cases only provided suggestive evidence of impairment. Poly-drug use 
in the studied cases also complicated the interpretation of the test results. Th e low frequency 
of detection of driving impairment in the clinical tests, despite the fact that most subjects were 
apprehended because they had been observed to be driving improperly, is of great concern 
and has been reported by other investigators and the writer has additional experience of the 
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problem. For example, a clinical examination was performed on one driver from the non-NPS 
use population and the physician judged him as not impaired. However, his blood results later 
revealed that he had 12 mg/L temazepam in his blood (among other substances) – a concentration 
that is associated with severe sedation and would surely have aff ected driving, even if tolerance 
had occurred [VI]. 
Another troublesome issue is whether tolerance should be taken into account in those 
DUID cases in which medicinal drugs are involved. Patients appropriately taking prescribed 
medications for long periods may develop tolerance to some of the pharmacological eff ects that 
impair driving. It could be argued that such individuals may not be impaired at blood levels that 
would impair others and therefore should not be penalised. However, the drivers in the study 
material had initially been apprehended for some concrete reason, accident, unsecure driving or 
similar, thus it is likely that the drug they had taken had indeed caused driving impairment and 
aff ected their driving behaviour. Furthermore, alcohol too induces tolerance but still the legal 
limits are the same for everybody, from moderate drinkers to alcoholics – why should the rules 
be diff erent for other substances that aff ect the CNS?
6.3 Concomitant use of other drugs in cases posi  ve for NPS
A characteristic phenomenon in all subsections of this study was that in the vast majority of the 
DUID and post-mortem cases the subjects positive for any of the studied substances were poly-
drug users. Th is is in accordance with previous studies on users of illegal drugs in Finland and 
other Nordic countries [11, 140,219,220, 221]. Th e studied NPS were nearly always used together 
with a spectrum of other psychoactive drugs from diff erent pharmacological groups. Other 
studies have shown that users of NPS have on average more previous experience from the use of 
illegal drugs than individuals that do not report use of NPS [ 222,51]. Th e results of the present 
study suggest that single experimenters and occasional users either do not get caught for DUI 
by the Finnish system or there are few such individuals in Finland. It could be that occasional 
experimenters are still relatively well in control of their lives and thus try to avoid colliding with 
generally accepted norms such as “driving under the infl uence of drugs is dangerous and thus 
forbidden”. When drug use advances into dependence/addiction, either such good intentions no 
longer exist, or, the loss of control over behaviour means that the good intentions cannot be 
put into practice. In some cases, especially with drivers suff ering from the antisocial personality 
disorder commonly encountered in problem drug users, colliding with the prevailing norms is 
one of the goals of driving under the infl uence [223]. Due to these factors, the common means 
of education about the dangers of DUID, or drug abuse in general, may have limited ability to 
regulate the behaviour of problem drug users.
6.4 User categorisa  on and diff erences between the studied 
substances
Even though users of NPS in this study share many factors and qualities regardless of the substance 
used, some diff erences between the studied substances could be observed in the concomitant use 
of other drugs. Th e drivers could be categorised into two groups according to the primary drug 
they are using: stimulant users and sedative users. Th is phenomenon was especially prominent in 
phenazepam-positive cases. Th e fi rst subgroup of phenazepam users had taken phenazepam as a 
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part of a spectrum of sedatives with relatively high concentration of the drug whereas the other 
group had used smaller doses of phenazepam presumably in order to manage the side eff ects 
of stimulant use. Alcohol was seldom used together with the studied stimulants, MDPV and 
2-DPMP, but more oft en encountered with the two CNS sedatives, phenazepam and pregabalin. 
Th e same was true for opioids in that they too were rarely used with the stimulants but more 
oft en with the sedatives. In post-mortem cases, however, stimulant NPS were frequently present 
together with opioids, suggesting that these stimulants are not particularly toxic on their own 
but may contribute to the fatal outcome when used together with opioids. In previous studies, 
opiate users have been shown to possess a higher mortality risk than those using amphetamines 
[212,224]. Also in this study, opioids were proportionally much more oft en present in post-
mortem cases than in DUID cases suggesting elevated mortality of NPS users who also abuse 
opioids. Apprehended drivers using stimulant NPS had high concentrations of the stimulant 
oft en combined with a modest concentration of sedatives, in most cases benzodiazepines. On 
the other hand, drivers with high concentrations of sedatives in most cases only had little or no 
stimulants in their blood. 
Previous research has suggested that the NPS users are younger than users of  more 
established abused drugs [225]. Th is was, however, not confi rmed in this thesis since the drivers 
in the study material were slightly older than in all DUID cases in Finland in 2007 (34.0 vs. 32.1 
years) and the MDPV-positive deceased were about the same age as the mean age in all fatal 
poisonings of users of illicit drugs in Finland in 2012 [11].
Both in DUID and post-mortem investigations, MDPV-positive females were signifi cantly 
younger than MDPV-positive men. Similar observations on gender diff erences in the age 
profi le of NPS users have not been reported elsewhere and the reason for these considerable age 
diff erences remains, for the most part, unclear. Th ese age diff erences are in confl ict with previous 
results on gender diff erences in drug use in general, although the earlier research has mostly 
concentrated on age at fi rst drug use [226].Th e fi nding is also in confl ict with previous studies 
on Finnish DUID off enders where no age diff erences were found between genders [140]. Th ere 
are studies that have revealed diff erences between the two genders in terms of the acquisition, 
escalation and relapse phases of drugs use [ 227] and it is likely that these diff erences are also 
present in the usage of NPS. Some studies have suggested that females are more likely to abuse 
stimulants than other classes of drugs [227,228]. In this thesis, however, as is true for most 
studies on drugs users, the number of males was about three times that of females for every 
studied substance.
6.5 Court cases of MDPV-posi  ve apprehended drivers
As a part of the study, a group of drivers positive for MDPV was characterised more closely 
by looking at the court documents of the DUID cases. It was found that many of the MDPV-
positive drivers were well outside mainstream society since more than a third of them were 
without a fi xed abode and many were very frequent visitors at the district court. Similar results 
for DUID off enders have been seen in a previous Finnish study [229]. Based on the results from 
this thesis, it is suggested that the high proportion of individuals without a fi xed abode can be 
generally attributed to the social status of users of MDPV – it does not seem to be a trendy club 
drug for the affl  uent but rather is used by individuals with a history of drug use and little control 
over their choices in life.
General Discussion
45
6.6 Geographical distribu  on on NPS and changes in prevalence
In terms of geographical distribution, MDPV was mainly detected in the capital area whereas a 
considerable portion of the phenazepam cases were from the area close to the Russian border. 
Th is probably refl ects the delivery routes of the two drugs but also diff erences in drug use 
patterns in urban and rural areas. NPS have in general been found to be more prevalent in high 
population density locations, colleges and universities [201]. Th e geographical distribution of 
MDPV changed somewhat over time probably indicating the development of new distribution 
channels or users’ awareness of the existence of the drug. However, at the same time the number 
of MDPV-positive cases decreased aft er it was banned in Finland. In addition to the impact 
of banning MDPV, the observed decrease both in DUID and post-mortem cases positive for 
MDPV could also be due to the typical “evolution” or “life cycle” of NPS [230]. Earlier studies 
from the UK have suggested that changes in prevalence may refl ect alterations in price, quality 
and availability of the drug rather than being a direct consequence of the banning [222]; this may 
be true in Finland as well. 
Th e length and character of the life cycle seems to vary between the studied NPS. MDPV 
was common for several years and in 2015 it is still encountered both in DUID and post-
mortem cases, albeit much less oft en than during the peak years. Th e other studied stimulant, 
desoxypipradrol, never became an internationally popular stimulant the way MDPV did. It 
was mainly encountered in Finland and the UK and only for a limited time. Desoxypipradrol is 
still occasionally found in the post-mortem investigations in Finland but while MDPV clearly 
took its place among the more established drugs of abuse in Finland, desoxypipradrol fi ndings 
have become quite rare aft er the brief peak in 2010–2011.  Currently in 2015, α-PVP is the most 
common stimulant NPS in FInland.
 At present, all new substances are equally available all over the world, thanks to the Internet, 
which lowers the threshold of experimenting with new substances. Th e fact that Finland has been 
among the most active countries in reporting new substances to EMCDDA suggests that even 
though Finland is not located on the main delivery routes of abused drugs, Finns enjoy trying 
new substances perhaps even more eagerly than other Europeans. However, the comparison 
between countries is somewhat diffi  cult since not every country has the same possibilities and 
prerequisites for continuously adding new substances into the screening programs. 
6.7 MDPV in suicides
In terms of the manner of death in the post-mortem cases studied in this thesis, MDPV was 
proportionally more prevalent in suicides than the more conventional abused drugs. Some earlier 
studies have suggested that the use of synthetic cathinones may be associated with depression 
and schizophrenia-like symptoms [56,231,232,233], which could partly explain the fi ndings 
in this study. Unfortunately, the background information in the post-mortem cases frequently 
does not include suffi  cient history of mental illnesses of the deceased, which complicates any 
further interpretations on the issue. However, MDPV has gained a reputation as a “bad drug” 




6.8 Pregabalin as an example of prescrip  on drug abuse
Pregabalin has been available as a medicinal drug for little over 10 years and has gradually gained 
popularity in the treatment of epilepsy and neuropathic pain, for which it has been approved, 
and also in some off -label indications such as migraine and insomnia [234,235]. In the present 
study, pregabalin was detected in high concentrations and mainly together with other abused 
drugs. Of all the 206 cases in which pregabalin was found, in only one of them could it have been 
used for an appropriate medical purpose. At the time of the study in this thesis, pregabalin was 
generally not prescribed for users of illegal drugs in Finland since clinicians had already noticed 
that addicts took large doses of pregabalin in order to boost the euphoric eff ects of opioids they 
were abusing [personal communication]. Th erefore, fi nding pregabalin in combination with 
illegal drugs allowed the assumption that pregabalin was being abused. 
In all of the individual studies on DUID cases in this thesis the studied substances were 
found in high concentrations. In post-mortem cases, however, the concentration of NPS was 
not always particularly high, indicating that the NPS did not play a signifi cant role as a sole 
intoxicant in fatal poisonings. Th e number of cases studied is exceptionally high when compared 
to previous research on NPS. Th e reported cases cover both genders and a broad age range 





When the analysis of blood samples for DUID cases is performed in a standardised and 
comprehensive manner so that most drugs of abuse are likely to be detected as soon as possible 
aft er they have entered the drug marketplace, the data obtained provide an excellent platform to 
study the prevalence and user characteristics of NPS. Th ere are more fi ndings of abused drugs 
in DUID cases than there are in post-mortem investigations so substances with low prevalence 
are more likely to be encountered amongst DUID cases. In this thesis, both sources of data have 
been utilised and together they provide an excellent body of material for research.
In the studies included in this thesis, serum concentrations of the NPS in drivers were 
oft en high, even when compared with the blood concentrations in fatal poisonings, suggesting 
signifi cant impairment of psychomotor performance and driving ability. Th e incidence of 
MDPV decreased aft er it was banned both in DUID and in post-mortem investigations. Both in 
drivers and deceased, the NPS were usually found together with more established drugs of abuse. 
Th is was true also with pregabalin; in most of the pregabalin-positive cases drugs of abuse were 
also found indicating that pregabalin was being abused rather than being used for a prescribed 
medical purpose. 
Drivers suspected of DUID could be categorised into two distinct groups: those whose 
drug use suggested that they were seeking a sedative “high” and those whose drug use suggested 
they were seeking a stimulant “high”. Signifi cant diff erences in the blood concentrations and 
concomitant use of other drugs were found between these two groups. Even though sedatives 
were used by both groups, their serum concentrations were signifi cantly higher in individuals 
who did not take stimulants concomitantly and it seems likely that the stimulant users took 
sedatives to manage stimulant side-eff ects. 
Th e frequency of suicide was extraordinarily high in those post-mortem cases which were 
positive for MDPV. Since the overall number of MDPV-positive post-mortem cases was low, 
interpretation of this data is best left  until additional information is available. However, similar 
results have been obtained in other studies on synthetic cathinones. 
Since NPS are usually detected along with other more established, banned, drugs of abuse, 
the importance of NPS fi nding for the prosecution of DUID cases is limited. Th e drivers would 
have been prosecuted even without the detection of the NPS because of the presence of the 
banned drugs. However, NPS have adverse eff ects on the psychomotor performance of the driver 
and may interact in unpredictable ways with other psychoactive drugs (although there is limited 
data to indicate the magnitude of such eff ects), increasing the risk of accidents and serious or 
life-threatening injury for the driver and the public. Providing regulatory authorities with the 
information needed to make early decisions on banning NPS will help to minimise these risks. 
In fatal poisonings positive for NPS, the forensic pathologist frequently implicated the NPS 
in the cause of death, usually along with other substances. Th us, for post-mortem investigations, 
it is important to include new substances into the screening program as soon as possible aft er 
they appear in the user population in order to provide the forensic pathologist with all the 
relevant toxicological data about the case.
Aft er the termination of the study described in this thesis, new substances (e.g. α-PVP, PV8, 
ethylphenidate, etizolam) have emerged in addition to further cases involving the NPS studied 
in this thesis. Monitoring NPS will continue and, where possible, also the assessment of trends in 
the use of NPS. Th e rapid emergence of new substances creates an endless demand for research 
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on NPS in order to provide health care professionals, toxicologist, clinicians and law-makers 
with necessary information. Th e abuse of prescription drugs is a growing phenomenon which 
also needs to be further investigated so that the correct dimensions of the problem and suitable 
measures to handle it can be developed.
Future research is needed in order to understand the epidemiology, pharmacology, clinical 
eff ects, and management of the problem of new abused drugs. Effi  cient and reliable analytical 
detection of these substances are required to enable their monitoring in diff erent situations 
such as those studied in this thesis (DUID and post-mortem cases) and others such as drug 
rehabilitation institutions, drop-in centres, needle exchange programs, youth drug recovery 
homes, etc. Th e results presented in this thesis, and those of future scientifi c research, will help to 
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